The QualityStocks Daily Tuesday, August 27th, 2024

Today's Top 3 Investment Newsletters

QualityStocks(ADXN) $11.5800 +51.17%

MarketClub Analysis(ENSC) $0.6444 +47.06%

360 Wall Street(TRIB) $2.5000 +23.15%

The QualityStocks Daily Stock List

AbCellera Biologics (ABCL)

MarketClub Analysis, MarketBeat, Schaeffer's, The Street, BUYINS.NET, Zacks, Trades Of The Day, StreetInsider, StocksEarning, InvestorPlace, InsiderTrades, Early Bird and Daily Trade Alert reported earlier on AbCellera Biologics (ABCL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

AbCellera Biologics Inc. (NASDAQ: ABCL) (FRA: 8QQ) is a pharmaceutical firm focused on building an antibody discovery and development platform that searches, decodes, and analyzes natural immune systems to find antibodies that can be developed to prevent and treat illnesses.

The firm has its headquarters in Vancouver, Canada and was incorporated in 2012, on November 8th by Daniel Da Costa, Véronique Lecault, Kathleen Lisaingo, and Carl Lars G. Hensen. It operates as part of the biotechnology industry, under the healthcare sector. The firm primarily serves consumers in Canada.

AbCellera Biologics uses proprietary hardware, software, and tools along with the latest data science to operate as strategic partners and help develop optimized solutions faster for any program. It is party to a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting 2 undisclosed GPCR targets; and a research collaboration and license agreement with Eli Lilly and Co. It is also party to a strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions. This is in addition to having a collaboration with Viking Global Investors and ArrowMark Partners.

The enterprise’s preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. IND submissions for both ABCL575 and ABCL635 are anticipated in 2025.

AbCellera Biologics recently broadened its antibody discovery partnership with Eli Lilly, an innovative pharmaceutical firm. This move will deepen their partnership and potentially increase their impact on patients across multiple therapeutic areas. This is in addition to opening the firm to new growth and investment opportunities.

AbCellera Biologics (ABCL), closed Tuesday's trading session at $2.61, off by 2.974%, on 1,266,690 volume. The average volume for the last 3 months is 269,312 and the stock's 52-week low/high is $2.40/$6.055.

Addex Therapeutics (ADXN)

QualityStocks, Prism MarketView, StockEarnings, MarketBeat, Prism Market View, MarketClub Analysis, INO Market Report and 247 Market News reported earlier on Addex Therapeutics (ADXN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Addex Therapeutics Ltd (NASDAQ: ADXN) (FRA: APE0) is a development-stage biopharmaceutical firm which is focused on discovering, developing and commercializing small-molecule pharmaceutical products for central nervous system disorders.

The firm has its headquarters in Geneva, Switzerland and was incorporated in 2002 by Mark Epping-Jordan, Timothy Dyer and Vincent Mutel. Prior to its name change in March 2012, the firm was known as Addex Pharmaceuticals Ltd. It operates as part of the scientific research and development services industry, under the health care sector. The firm has two companies in its corporate family and mainly serves consumers in Switzerland.

The company is party to a license and collaboration agreement with the Charcot Marie Tooth Association and Indivior PLC. It is also party to an agreement with Janssen Pharmaceutical Inc., which entails the development of a formulation for the treatment of anxious depression and schizophrenia. It is focused on discovering oral molecule allosteric modulators of G-protein coupled receptors.

The enterprise’s product pipeline comprises of GABAB PAM, which is indicated for the treatment of addiction; and a formulation dubbed ADX71149, which has been developed for the treatment of undisclosed central nervous system disorders and epilepsy. It also develops a formulation known as Dipraglurant, which is indicated for the treatment of dystonic and Parkinson’s disease levodopa-induced dyskinesia.

The company recently released its latest financial results for 2021, which show increases in income, with its CEO noting that they’d made significant progress in its pipeline. It plans to extend its strategic collaboration with Indivior Plc to advance it GABAB PAM formulation, which has shown promise in the treatment of addiction.

Addex Therapeutics (ADXN), closed Tuesday's trading session at $11.58, up 51.1749%, on 16,755,181 volume. The average volume for the last 3 months is 1.61M and the stock's 52-week low/high is $5.00/$27.90.

Ensysce Biosciences (ENSC)

MarketClub Analysis, QualityStocks, PennyStockProphet, Broad Street, The Stock Dork, PennyStockScholar, INO Market Report and 247 Market News reported earlier on Ensysce Biosciences (ENSC), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Ensysce Biosciences Inc. (NASDAQ: ENSC) (OTC: ENSCW) is a clinical-stage biotechnology firm that is focused on the development of prescription medications.

The firm has its headquarters in La Jolla, California. Prior to its name change, the firm was known as Leisure Acquisition Corp. It operates as part of the pharmaceutical medicine manufacturing industry, under the biotech and pharma sub-industry, in the health care sector. The firm serves consumers across the globe.

The company’s objective is to help prevent deaths caused by opioid abuse and offer safer options for the treatment of severe pain. It is focused on developing tamper-proof opioids through the use of multi-pill abuse resistance platforms and Trypsin activated abuse protection. This will prevent both drug overdoses and drug abuse, which will in turn help contain the prescription drug abuse epidemic.

The enterprise’s product pipeline comprises of its proprietary pro-drug technologies which have been designed to enhance the care of patients living with chronic pain and decrease the economic and human costs linked to prescription drug abuse. Its trypsin activated abuse protection and abuse-resistant opioid product candidate is known as PF614. The enterprise has also designed a large biomolecule delivery platform which uses SWCNT (single walled carbon nanotubes) to produce gene therapy and immunology products.

The company is focused on pursuing its more-advanced clinical stage product candidates and developing additional potential candidates. The success and approval of the company’s formulations will not only bring in more investors into the company as well as additional revenue but will also boost its growth.

Ensysce Biosciences (ENSC), closed Tuesday's trading session at $0.6444, up 47.0645%, on 95,114,387 volume. The average volume for the last 3 months is 1.225M and the stock's 52-week low/high is $0.361/$2.06.

Trinity Biotech (TRIB)

TradersPro, Hot Shot Stocks, SmarTrend Newsletters, MarketBeat, Marketbeat.com, BUYINS.NET, QualityStocks, StocksEarning, StreetAuthority Daily, TopPennyStockMovers, StockEarnings, Zacks, PoliticsAndMyPortfolio, StreetInsider, The Street, Greenbackers and Daily Markets reported earlier on Trinity Biotech (TRIB), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Trinity Biotech Plc (NASDAQ: TRIB) (FRA: TRBA) is focused on developing, manufacturing and selling medical diagnostic products for the diagnostic market.

The firm has its headquarters in Bray, Ireland and was incorporated in June 1992 by Denis R. Burger and Ronan O’Caoimh. It operates as part of the pharmaceutical and medicine manufacturing industry, under the health care sector. The firm has seventeen companies in its corporate family and serves consumers around the globe.

The company operates through the Rest of the World and the Americas geographical segments. The latter segment mainly focuses on the United States while the former segment primarily serves consumers in Europe, Asia and Africa.

The enterprise provides clinical lab products like diagnostic tests which are used to detect infectious ailments like SARS-CoV-2 and lyme disease, sexually transmitted illnesses like herpes and syphilis, and varicella, rubella, cytomegalovirus, toxoplasmosis and other viral pathogens. It also provides products for in-vitro haemoglobin A1c diagnostic testing, which is used to diagnose and monitor diabetes, as well as identify individuals at risk of developing the disease. In addition to this, it also manufactures reagent products like ACE, oxalate and lactate, for the diagnosis of haemolytic anemia, as well as kidney and liver diseases.

The company plans to launch its Uni-gold rapid SARS-CoV-2 antigen test in Europe after obtaining approval, after which it will unveil the product in other markets. Given that the pandemic is still raging on and new variants are emerging, the success of this product will be a significant growth driver of the business and bring in additional revenue as well.

Trinity Biotech (TRIB), closed Tuesday's trading session at $2.5, up 23.1527%, on 69,703,253 volume. The average volume for the last 3 months is 4.246M and the stock's 52-week low/high is $1.49/$4.588.

Tantech Holdings (TANH)

QualityStocks, BUYINS.NET, TradersPro, The Online Investor, StreetInsider, INO.com Market Report, TraderPower, MarketClub Analysis, StockMarketWatch, Premium Stock Alerts, MarketBeat, InvestorPlace and Investing Futures reported earlier on Tantech Holdings (TANH), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Tantech Holdings Ltd (NASDAQ: TANH) is focused on the development and manufacture of bamboo-based charcoal products for various applications, which include cleaning, agricultural, purification, heating, household cooking and industrial energy.

The firm has its headquarters in Lishui, the People’s Republic of China and was incorporated in 2001, on November 19th by Zheng Yu Wang. The firm serves consumers across the globe, with a focus on China.

The company operates through the Electric vehicle, Trading and Consumer product segments. The electric vehicle segment is focused on the provision of electric control systems for electric cars, auto parts, Li-ion batteries and solar cells. The trading segment is focused on the exportation of charcoal products. On the other hand, the consumer product segment offers barbecue charcoal, deodorization and purification products and cleaning products developed for the domestic market. These products are sold under the Charcoal Doctor brand.

The enterprise’s other products include a liquid byproduct that can be used in fertilizers, toilet cleaners, specialized soaps, lotions, detergents and disinfectants known as bamboo vinegar. This byproduct can also be used in different agricultural applications. In addition to this, the enterprise is also involved in the development and sale of specialty electric vehicles like funeral cars, special emergency vehicles, electric cleaning cars and brushless cleaning cars, as well as electric logistics cars and electric buses.

The firm recently reported its latest financial results for the first half of 2021, with its CEO noting that the firm is focused on expanding into the specialty vehicle market by shifting its business from being engaged in consumer product sales solely.

Tantech Holdings (TANH), closed Tuesday's trading session at $0.1859, up 20.4016%, on 143,869,174 volume. The average volume for the last 3 months is 3.492M and the stock's 52-week low/high is $0.1211/$3.94.

International Business Machines Corp. (IBM)

FreeRealTime, The Street, InvestorPlace, Kiplinger Today, StockMarketWatch, IT News Daily, StreetAuthority Daily, internetnews, Schaeffer's, The Online Investor, Market Intelligence Center Alert, Daily Trade Alert, MarketClub Analysis, StocksEarning, Money Morning, TopStockAnalysts, StreetInsider, MarketBeat, Zacks, All about trends, Investopedia, Trades Of The Day, Top Pros' Top Picks, Profit Confidential, The Wealth Report, Uncommon Wisdom, Wyatt Investment Research, Barchart, Louis Navellier, ProfitableTrading, Dividend Opportunities, Daily Profit, Wealth Insider Alert, internet, TheStockAdvisors, SmarTrend Newsletters, The Street Report, Daily Wealth, MarketWatch, Daily Markets, The Motley Fool, WStreet Market Commentary, Investors Alley, Early Bird, Money and Markets, Street Insider, Cabot Wealth, Investing Daily, TheStockAdvisor, SiliconValley, Insider Wealth Alert, StrategicTechInvestor, CustomerService, StockEarnings, Trading Markets, The Growth Stock Wire, Forbes, InvestorGuide, FeedBlitz, Marketbeat.com, DividendStocks, iStockAnalyst, Market Intelligence Center, Money Wealth Matters, Wall Street Daily, TradingMarkets, FNNO Newsletters, Coattail Investor, TipRanks, The Tycoon Report, Investor Guide, Daily Dividends, CNBC Breaking News, QualityStocks, Investment U, SmallCap Network, INO.com Market Report, StockTwits, Dynamic Wealth Report, Super Stock Investor, Darwin Investing Network, Investor Update, Shah's Insights & Indictments, Eagle Financial Publications, Greenbackers, Energy and Capital, INO Market Report, Stockhouse, Total Wealth, Penny Stock Buzz, Options Elite, InvestmentHouse, ChartAdvisor, Short Term Wealth, Trade of the Week, The Trading Report, Stock Barometer, Trader Prep, Wealth Daily, Investing Lab, Market Authority, TradingAuthority Daily, BullDogReporter, Trading Concepts, AllPennyStocks, BestOtc, All Star Investor, Quant Ratings Team, SmallCapVoice, CRWEFinance, Stock Gumshoe, Trading Tips, CRWEPicks, Investing Futures, Market Wrap Daily, internetnews.com, The Best Newsletters, Alternative Energy, FutureMoneyTrends.com, PennyOmega, StreetAuthority Financial, Leeb's Market Forecast, Inside Investing Daily, OilAndEnergyInvestor, GorillaTrades, InvestorsObserver Team, Investor News, Investment House, Beacon Equity Research, Investment Contrarians, TraderPower, Traders For Cash Flow, Trident Confidential, Inside Trading, Jea Yu, Equities.com, Hit and Run Candle Sticks, Hiral Ghelani, Wealthpire Inc., Willy Wizard, Free Hot Penny Stocks, AfterMarketNews, Wall Street Greek, SwingTradeOnline, Profitable Trader Authority, Smart Investing Society, Power Profit Trades, PennyToBuck, Penny Detectives, Stock Up Featured, StockHotTips, CNBC, Buzz Stocks, DrStockPick, InvestorIntel, The Night Owl and The Stock Dork reported earlier on International Business Machines Corp. (IBM), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Donald Trump, the GOP presidential nominee, recently posted fake images which suggest that Taylor Swift and her fans are supporting him in the upcoming election. The images posted by the former president seem like deepfakes generated by artificial intelligence and have been shared by right-wing accounts on social media accounts that have a history of spreading misinformation. These images are accompanied by a message from Trump, who posted, “I accept!” on X.

In one of the pictures, the pop star’s fans, popularly known as Swifties, can be seen smiling and wearing T-shirts written “Swifties for Trump.”

Another image had a fake headline beneath a satire tag, which suggests that Swifties turned to the former president after Swift cancelled one of her concerts in Vienna this month. A third image portrays the pop star dressed as Uncle Sam, a U.S. Army character for a recruitment poster from WWI, imploring people to vote for Trump.

Swift, who hasn’t endorsed a presidential candidate for this year’s election publicly, supported the Democratic Party during the last elections. The singer also criticized Trump publicly during his presidency, especially amid countrywide protests following the murder of George Floyd by police officers.

In 2020, the pop star posted on X (Twitter at the time), “After stoking the fires of white supremacy and racism your entire presidency, you have the nerve to feign moral superiority before threatening violence?” She continued, adding “We will vote you out in November.”

Swift hasn’t yet responded to the former president’s posts.

These images are some of the many other AI-generated pictures Trump has posted in the last couple of days. Trump is known for spreading misinformation, having recently shared an image generated by AI that portrays presidential nominee Kamala Harris speaking at a communist rally at the Democratic National Convention. The convention is being held this week in Chicago.

In addition to this, the GOP party candidate also shared a deepfake video of himself and Elon Musk dancing to “Stayin’ Alive” by the Bee Gees. Musk, who owns X, has endorsed the former president. This comes after the billionaire held a two-hour conversation with Trump on X last week.

In other news, Trump claimed that a real photo with thousands of supporters who attended a campaign rally held by Kamala Harris and Tim Walz, her running mate, was generated by artificial intelligence. On Truth Social, his social media platform, Trump claimed that the crowds in Kamala’s photo didn’t exist.

These cases of deepfakes being used to influence opinions regarding the upcoming elections create a broader need for industry regulation so that the many companies that focus on AI innovations which are truly helpful, such as International Business Machines Corp. (NYSE: IBM),  don’t get mired in the negative press that wrong users of AI tools generate.

International Business Machines Corp. (IBM), closed Tuesday's trading session at $198.73, up 0.3788261%, on 2,617,229 volume. The average volume for the last 3 months is 1.35M and the stock's 52-week low/high is $135.87/$199.40.

Mind Medicine Inc. (MNMD)

QualityStocks, InvestorPlace, Schaeffer's, PsychedelicNewsWire, MarketBeat, TradersPro, The Wealth Report, The Street, The Stock Dork, MarketClub Analysis, Daily Trade Alert, Wealth Daily and Trades Of The Day reported earlier on Mind Medicine Inc. (MNMD), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

The U.S. Food and Drug Administration (FDA) recently rejected an application to approve the use of MDMA as a treatment for post-traumatic stress disorder (PTSD). The MDMA formulation, developed by Lykos Therapeutics, would have been administered in combination with psychotherapy if it had been approved.

In its rejection, the federal agency requested for more clinical trials to be done to gather additional data on the drug’s effectiveness and safety. This decision comes just months after the FDA’s advisory committee determined that the application made by Lykos was lacking on both fronts.

The decision is a significant change in the drug’s trajectory, seeing as in 2017, the FDA approved the psychedelic’s review process. This was driven by promising findings in the early stages which suggested that MDMA, when administered together with psychotherapy, could provide relief to the millions with post-traumatic stress disorder.

During this period, Lykos applied for approval to market its psychedelic formulation, called midomafetamine. In its application, the company included strong data from a pair of phase 3 trials that demonstrated decreased scores for symptoms of PTSD.

The FDA declined, however, and requested a second trial, which needs to include improved policies following misconduct involving therapists who abused a patient. The panel, made up of 11 members, voted on the matter, with 9 agreeing that the evidence provided didn’t demonstrate the effectiveness of the drug. Additionally, 10 of them ruled that the drug’s potential benefits didn’t outweigh the risks.

The company’s chief executive, Amy Emerson, revealed that carrying out another trial would take a couple of years.

Soon after the rejection, editors at the “Psychopharmacology” journal retracted three papers from scientists associated with MAPS Public Benefit Corp. A pair of the papers analyzed half a dozen clinical trials that were included in the submission made to the FDA. In their report, the editors highlighted violations in protocol that amounted to unethical conduct.

Additionally, Lykos announced that Rick Doblin would be stepping down from the company’s board to allow him to freely advocate for psychedelic treatments. Doblin pioneered the MDMA treatment. Lykos also announced that it would be letting go 75% of its workforce.

Despite this setback, scientists could learn a lot from Lykos and its journey of studying treatments for conditions such as addiction and depression. University of California’s David Olson notes that it is possible to develop psychiatric medications while avoiding psychotherapy completely during trials.

He explained that if a drug was effective and safe, there is no reason a physician couldn’t prescribe the drug with psychotherapy because the FDA didn’t regulate medicine as a practice.

Many startups in the psychedelics space, such as Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), will be reflecting deeply about what has happened to the MDMA application submitted by Lykos Therapeutics. Any lessons they can learn will be invaluable because implementing the needed changes can make or break years of work invested in developing a psychedelic drug candidate.

Mind Medicine Inc. (MNMD), closed Tuesday's trading session at $6.23, up 1.7974%, on 756,568 volume. The average volume for the last 3 months is 76,184 and the stock's 52-week low/high is $2.41/$12.22.

Kandi Technologies Group Inc. (KNDI)

Green Car Stocks, QualityStocks, MarketClub Analysis, InvestorPlace, Schaeffer's, The Street, StockMarketWatch, Hit and Run Candle Sticks, StreetInsider, TraderPower, Jason Bond, Greenbackers, Alternative Energy, GreatStockPix, Wall Street Resources, GreenCarStocks, BUYINS.NET, Investing Futures, MarketBeat, China Stock Alerts, TradersPro, Money Morning, Penny Stock Rumble, ProfitableTrading, Marketbeat.com, SmarTrend Newsletters, StreetAuthority Daily, Trades Of The Day, TradingMarkets, The Wealth Report, TipRanks, TopStockAnalysts, FeedBlitz, Energy and Capital, Dynamic Wealth Report, DrStockPick, Money and Markets, CRWEWallStreet, Street Insider, CRWEPicks, CRWEFinance, CoolPennyStocks, ChartAdvisor, Weekly Wizards, BullRally, BestOtc, Barchart, Daily Trade Alert, StockEarnings, SmallCapNetwork, Profit Confidential, PennyTrader Publisher, PennyToBuck, PennyStockVille, PennyOmega, PennyInvest, SmallCapVoice, HotOTC, Stock Traders Chat, INO.com Market Report, StockEgg, MadPennyStocks, StockHotTips, InvestorsUnderground, Investors Alley, StockRich, InvestorGuide, Investor Ideas, Rick Saddler and Willy Wizard reported earlier on Kandi Technologies Group Inc. (KNDI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

A recently published study from the American Council for an Energy-Efficient Economy (ACEEE) has revealed that adopting more efficient battery electric vehicles (BEVs) could alleviate stress on power grids and lower charging costs by nearly 30%. The research also notes that increasing the average efficiency of electric cars could cut EV prices by nearly $5,000 and allow EV drivers to lower both their purchase and operational costs.

Electric cars are poised to replace the United States’ massive fleet of internal combustion engine (ICE) cars over the next couple of decades to help the country cut emissions from transportation and achieve its carbon neutrality goals. However, EV technology is still a work in progress, and companies in related industries are consistently working to improve EV efficiency, range and performance without impacting their affordability.

According to American Council for an Energy-Efficient Economy senior transportation research associate and lead study author Peter Huether, the nascent electric vehicle sector must make the same efficiency gains ICE cars have made throughout their history. Improving efficiency is especially crucial for electric cars as efficiency is intrinsically tied to energy use and overall range, making it one of the most important EV-related metrics to consider.

Research from the ACEEE shows that pursuing efficiency improvements will cut electric vehicle prices, lower charging costs and limit stress on the energy grid. Furthermore, ACEEE’s research found that cutting the battery size for the Tesla Model Y, currently the best-selling EV in the country, by around 40% without compromising the range could lead to savings of up to $4,800. The ACEEE notes that despite its popularity, the Model Y isn’t the most efficient electric vehicle in the U.S. market.

Compared to the Model Y, which is 3.5 miles/kWh, the Ioniq 6 by Hyundai can achieve 4.2 miles/kWh, while the Lucid Air Pure was the first battery electric car to reach the five miles/kWh threshold. As Huether says, making electric cars more efficient will be critical to making them cheaper and reducing pollution. If, for instance, automakers can replace the rare earth metals used in EV batteries with more accessible alternatives, Huether says, they will be able to manufacture more EVs and accelerate the world’s transition from fossil-fuel vehicles to zero-emission cars.

The report also says automakers can pursue higher electric vehicle efficiency by choosing lighter designs with less drag and investing in drivetrain technology R&D. With electric vehicle demand waning in recent months amid high purchase costs and limited charging infrastructure, efficiency could help lower EV purchase and operational costs.

The onus is now on the different EV and battery makers, such as Kandi Technologies Group Inc. (NASDAQ: KNDI), to ramp up their R&D efforts so that they can quickly bring to market EVs with the needed high-efficiency levels to tap the grid benefits and affordable charging potential envisaged in the research above.

Kandi Technologies Group Inc. (KNDI), closed Tuesday's trading session at $1.8, up 0.5586592%, on 35,635 volume. The average volume for the last 3 months is 1.535M and the stock's 52-week low/high is $1.66/$3.67.

Momo Inc. (MOMO)

QualityStocks, StocksEarning, MarketClub Analysis, StockEarnings, InvestorPlace, Schaeffer's, Marketbeat, Market Intelligence Center Alert, Zacks, The Street, Trades Of The Day, Kiplinger Today, Daily Trade Alert, StreetInsider, The Street Report, Marketbeat.com, BUYINS.NET, The Online Investor, FreeRealTime, INO.com Market Report, ChineseWire, Trading Concepts, Louis Navellier, TradersPro, Wealth Insider Alert, StreetAuthority Daily, TopStockAnalysts, Money Morning, Investopedia, DividendStocks, Daily Wealth, PennyDoctor, TipRanks, Greenbackers, StockMarketWatch, StocksImpossible, Street Insider, OTCBB Journal, Early Bird, First Penny Picks, ChartAdvisor, Barchart, CrashTrade, Investing Signal, InvestmentHouse, Jason Bond, AskSlapper, Orbit Stocks, Profit Confidential, Promotion Stock Secrets, Short Term Wealth, Terry's Tips, The Best Newsletters, The Stock Dork and One Hot Stock reported earlier on Momo Inc. (MOMO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

A safety group is calling out Meta subsidiary and global communication platform WhatsApp for not taking steps to stop users from sharing images depicting child abuse. The Internet Watch Foundation (IWF), an organization that finds and removes child abuse images from the internet, alleges that Meta isn’t doing enough to protect children and called on the tech giant to intensify efforts to stop the sharing of such images on WhatsApp.

According to the safety group, Meta could use content-moderation mechanisms to prevent the proliferation of child abuse images on the communication app. WhatsApp is the most popular mobile communication platform on the globe and has billions of users across dozens of countries. A spokesperson from WhatsApp noted that users can directly report other users who push “heinous material,” so the company can ban them and report the offending users to the National Center for Missing and Exploited Children.

Alluding to a recent incident involving explicit images and a former BBC news presenter, IWF chief technology officer Dan Sexton says Meta has chosen not to prevent “indecent imagery” from spreading on WhatsApp. He asked how Meta would prevent child abuse images from being shared on WhatsApp in the future and wondered if there are any mechanisms stopping people from sharing such images on WhatsApp today.

He explained that there are no mechanisms to stop the proliferation of child abuse images on videos on WhatsApp even though Meta, the police and even the general public know such images are shared on the platform. However, a WhatsApp spokesperson argued that the app had better safety measures than other applications in the communications segment, such as end-to-end encryption.

The spokesperson said end-to-end encryption helps to keep people of all ages safe and noted that WhatsApp has come up with “robust” safety features that allow it to spot, prevent and deal with abuse without compromising users’ privacy. On the other hand, National Crime Agency acting director of intelligence Rick Jones argued that even though the technology to identify and combat child abuse images already exists, companies such as Meta are intentionally designing messaging platforms that don’t allow the effective use of this technology.

In some cases, Jones said, messaging platforms are designed in such a way that they can’t use this safety technology at all. Additionally, he said end-to-end encryption only hides illegal behavior in messaging platforms and doesn’t protect customers in any way. Similarly, United Kingdom safeguarding minister Jess Phillips called on social media platforms to incorporate “robust detection measures” into their systems to ensure they aren’t safe spaces for criminals.

More countries are likely to grow increasingly concerned about the different forms of crime that are perpetuated on social media and video-sharing platforms. Entities that have a stake in these segments, such as Momo Inc. (NASDAQ: MOMO), need to come up with innovations that will detect and weed out any criminals.

Momo Inc. (MOMO), closed Tuesday's trading session at $6.52, off by 1.9549%, on 1,496,639 volume. The average volume for the last 3 months is 3.834M and the stock's 52-week low/high is $4.79/$9.69.

Canopy Growth Corp. (CGC)

InvestorPlace, Schaeffer's, The Street, StocksEarning, MarketClub Analysis, StockEarnings, Trades Of The Day, MarketBeat, Daily Trade Alert, Kiplinger Today, QualityStocks, The Online Investor, Wealth Insider Alert, Streetwise Reports, StreetInsider, CFN Media Group, Market Intelligence Center Alert, Investopedia, Zacks, StreetAuthority Daily, Stock Up Featured, The Wealth Report, Daily Profit, Top Pros' Top Picks, SmallCapVoice, Early Bird, StockMarketWatch, Lebed.biz, Wall Street Grand, SeriousTraders, INO Market Report, Profit Trends, Money Morning, BUYINS.NET, Louis Navellier, Cannabis Financial Network News, CNBC Breaking News, Investors Underground, Inside Trading, Jim Cramer, Outsider Club, StocksToBuyNow, Trading For Keeps, TradersPro, MarketClub, Technology Profits Daily, AllPennyStocks, Beat The Street, Wealth Daily, Cabot Wealth, VectorVest, CannabisNewsWire, Trading Concepts, Timothy Sykes, Profit Confidential, TheTradingReport, Insider Wealth Advice, Investment U, InvestmentHouse, Stock Gumshoe, Investors Alley, Rick Saddler, Raging Bull All Access, 24/7 Trader, Money and Markets and Tim Bohen reported earlier on Canopy Growth Corp. (CGC), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Ohio’s recreational marijuana market has experienced impressive growth, generating more than $11.5 million in sales in its first week. According to the state’s Commerce Department, Cannabis Control Division, the total revenue from adult-use cannabis sales reached $11,530,708 as of Aug. 10, 2024.

Sales officially began on Aug. 6, eight months after Ohio voters approved recreational cannabis legalization, with 57% of voters supporting the ballot measure. The average cost of an ounce of flower was $266. The data shows that 1,285 pounds of cannabis plant material and 173,043 units of processed products were sold.

Ohio’s medical marijuana market is also thriving, pulling in more than $8.3 million in sales in the same period. When recreational sales are factored in, the state’s annual revenue is expected to approach $1.3 billion. This amount would be much more than Michigan’s first-year cannabis sales revenue in 2020, which came in at $474 million for medical use and $510 million for recreational use. Conversely, Illinois recorded sales of about $11 million in the first week of 2020.

Currently, Ohio has 120 dual-use stores registered to sell marijuana for both recreational and medical purposes, up from 98 when recreational cannabis sales first started. The state intends to grant about 170 more licenses to increase retail options and 50 licenses set aside for social-equity candidates.

Despite the success, more than 70 cities across Ohio have enacted local bans preventing recreational cannabis entities from operating within their jurisdictions, as reported by Ohio State University’s Moritz College of Law.

Under the ballot initiative that legalized recreational marijuana, a 10% tax is applied to all nonmedical cannabis purchases. Revenue from this tax is allocated to five different state funds: the Marijuana Social Equity and Jobs Fund, the Recreational Use Tax Fund, the Host Community Marijuana Fund, the Substance Abuse and Addiction Fund, and the Cannabis Control Division and Tax Commissioner Fund. These funds are designed to address a range of needs, from social-equity initiatives to addiction services.

Meanwhile, large marijuana operators are moving quickly to capture market share. Ascend Wellness Holdings launched recreational sales at its Carroll store on Aug. 15, 2024, following its initial rollout at locations in Sandusky, Cincinnati, Piqua and Coshocton. Verano Holdings, based in Chicago, also began recreational sales at its five Zen Leaf stores across the state.

Recreational cannabis currently is legal in 24 states, the District of Columbia and two territories. The entire cannabis industry, including companies such as Canopy Growth Corp. (NASDAQ: CGC) (TSX: WEED), will be rooting for the industry in Ohio to grow and reach its full potential so that the consumers who need these products can access them legally and conveniently.

Canopy Growth Corp. (CGC), closed Tuesday's trading session at $5.58, off by 9.5624%, on 5,500,674 volume. The average volume for the last 3 months is 496,152 and the stock's 52-week low/high is $2.755/$19.20.

Curaleaf Holdings Inc. (CURLF)

InvestorPlace, QualityStocks, Kiplinger Today, MarketBeat, Cabot Wealth, Daily Trade Alert, Top Pros' Top Picks, The Online Investor, MarketClub Analysis, Profit Trends, Wealth Insider Alert, CannabisNewsWire, StreetInsider, Early Bird, Trading For Keeps, Trades Of The Day, The Street, Prism MarketView, TradersPro, Schaeffer's, Investment U, Zacks, wyatt research newsletter, Daily Profit, CFN Media Group, StreetAuthority Daily and Wyatt Investment Research reported earlier on Curaleaf Holdings Inc. (CURLF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

In Virginia, medical and recreational marijuana is legal, although retail sales and recreational marijuana dispensaries haven’t yet been launched following delays with the approval of a re-enactment clause. However, residents in the southwest region of the state can still access the drug easily, with many stores openly selling the substance. This is despite some of these businesses being raided by law enforcement last year.

The sale of marijuana in this part of the country is surprising, especially since the stores are in the most conservative parts of Virginia. There’s at least one marijuana store in Tazewell County and another in Wythe County, which saw the majority of their residents vote for Donald Trump. Washington County and Bristol also have multiple stores, with more than 65% of residents in both counties voting Republican.

This conflicts with how lawmakers in the region vote, with GOP lawmakers in the General Assembly nearly unanimously opposing the legalization of retail marijuana. Additionally, Governor Glenn Youngkin vetoed a measure that was approved by the Democrats. This measure would have limited the number of licenses marijuana stores that could be awarded to 350. This is only 54 licenses short of the total number of Alcoholic Beverage Control board stores in Virginia.

This move may not have worked in the governor’s favor, however, with some towns in the southwest region now having more marijuana stores than liquor stores. For instance, Marian has at least two marijuana stores and a liquor store while Bristol has nine marijuana stores and two liquor stores.

It appears that the lawmakers may not reflect the will of the people in this regard. This is also evidenced by analysis which shows that when legal marijuana is on the ballot, GOP voters vote for legalization. This is backed by red states, including Montana and Missouri, which have voted in favor of recreational marijuana.

Additionally, legal marijuana has been approved in counties that overwhelmingly voted in favor of the GOP in the presidential vote, with Vinton being the most procannabis and Republican county in Ohio.

One of the downsides to this market is that the products being sold to consumers haven’t been tested for safety. This means that consumers have no way of knowing what’s in the marijuana they are purchasing. Tests carried out on marijuana purchased from Radford showed that the drugs had high levels of cadmium, lead and arsenic, while marijuana purchased from Roanoke County was moldy.

The marijuana industry, including leading companies such as Curaleaf Holdings Inc. (CSE: CURA) (OTCQX: CURLF), hope that the adult-use marijuana market in Virginia gets underway and allows people to access tested products so that they don’t expose themselves to potentially tainted black market products.

Curaleaf Holdings Inc. (CURLF), closed Tuesday's trading session at $2.75, off by 13.522%, on 1,893,548 volume. The average volume for the last 3 months is 14.042M and the stock's 52-week low/high is $2.51/$6.40.

Meta Platforms (META)

Zacks, The Street, InvestorPlace, Early Bird, Schaeffer's, Investopedia, MarketClub Analysis, MarketBeat, The Online Investor, Kiplinger Today, INO Market Report, Cabot Wealth, TipRanks, Louis Navellier, Top Pros' Top Picks, The Daily Market Alert, The Night Owl, Money Wealth Matters, QualityStocks, AllPennyStocks, DividendStocks, Trading Tips, TradersPro, InsiderTrades, Investment House, FreeRealTime, Daily Wealth, MarketMovingTrends, Eagle Financial Publications, The Wealth Report, Inside Trading, TradeSmith Daily, Trading with Larry Benedict, TradingPub, InvestorIntel, CNBC Breaking News, Market Trends, Smartmoneytrading, Rick Saddler, The Stock Dork, Marketbeat.com, Top Pros Top Picks, StockReport, Stansberry Research, Investing Breakout, Investing Daily, Earnings360, Contrarian Outlook, Trade Out Loud, Investors Underground, Jea Yu, Jon Markman’s Pivotal Point, bullseyeoptiontrading, Smart Investing Society, The Investing Insider, Chaikin Analytics, Trading Pub, Timothy Sykes, wyatt research newsletter, Tim Bohen, 360 Wall Street, Empire Financial Daily, empirefinancialresearch, Financial Newsletter, The SmartMoneyTrading, iDigital Market, Mind Over Markets, Investor News, Prism MarketView, Investor's Business Daily, Jeff Bishop, Premium Stock Alerts, OTC Stock Review, 1 2 3 Trade Option and Hit and Run Candle Sticks reported earlier on Meta Platforms (META), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Mark Zuckerberg, the CEO of Meta Platforms (NASDAQ: META), has made a significant claim that puts the spotlight on the interaction between the U.S. government and social media giants during critical times. Zuckerberg alleges that senior officials from the Biden administration pressured Meta to censor content related to COVID-19 during the pandemic. This accusation underscores the complex relationship between government bodies and platforms that hold considerable influence over public discourse, especially in times of global health crises.

Meta, known for its vast social media network including Facebook, Instagram, and WhatsApp, plays a pivotal role in how information is shared and consumed worldwide. The company’s influence extends to billions of users, making any government interaction a matter of public interest. Zuckerberg’s claim, as highlighted by Skynews, suggests a direct involvement of the government in attempting to control the narrative around COVID-19 on one of the largest social media platforms.

On the financial side, Meta’s stock performance remains a key indicator of the company’s health and investor confidence. On the day in question, META reached a high of $524 on the NASDAQ. This figure not only reflects the company’s market value but also investor reactions to various factors, including corporate governance, market conditions, and potentially, the news of government interactions.

The stock’s performance could be seen as a testament to Meta’s resilience and its ability to navigate through controversies and external pressures. While the allegations of government pressure are serious, the market’s response, as indicated by the stock’s valuation, suggests confidence in Meta’s ongoing operations and its handling of such challenges.

Understanding the dynamics between Meta and the government, especially in the context of managing information during a pandemic, is crucial. It highlights the delicate balance between public health concerns, freedom of information, and the power dynamics between state actors and global tech giants. The financial metrics further complicate this narrative, offering a glimpse into how investors may perceive and react to such news.

To view the company’s most recent earnings release, visit https://ibn.fm/yiWxc

About Meta

Meta builds technologies that help people connect, find communities and grow businesses. When Facebook launched in 2004, it changed the way people connect. Apps like Messenger, Instagram and WhatsApp further empowered billions around the world. Now, Meta is moving beyond 2D screens toward immersive experiences like augmented and virtual reality to help build the next evolution in social technology. For more information, visit the company’s website at https://investor.FB.com.

Meta Platforms (META), closed Tuesday's trading session at $519.1, off by 0.3876266%, on 6,282,720 volume. The average volume for the last 3 months is 29,565 and the stock's 52-week low/high is $279.403/$544.23.

The QualityStocks Company Corner

PaxMedica Inc. (NASDAQ: PXMD)

The QualityStocks Daily Newsletter would like to spotlight PaxMedica Inc. (NASDAQ: PXMD).

PaxMedica (NASDAQ: PXMD), a leading biopharmaceutical company dedicated to advancing treatments for neurological disorders, today announced that the first patient suffering from the potentially fatal parasitic infection known as Human Africa Trypanosomiasis Brucei Rhodesiense ("HAT") in Malawi had been treated with PAX-101, an intravenous form of Suramin. The announcement noted that the Malawi Ministry of Health has informed PaxMedica that, following the treatment, the patient is recovering at home. The Rhodesiense strain of HAT is nearly 100% fatal if not treated promptly, and Suramin is considered the standard of care in Malawi and many East African countries.

"The first use of PAX-101 to treat a critically ill patient with Stage 1 HAT infection is an important milestone for the company following years of investment in the formulation and commercial scale-up of Suramin, the active pharmaceutical ingredient of PAX-101, with the company's supply chain partners. We were contacted by the government of Malawi after sustained shortages of IV Suramin in the region in the past year, and we could not ignore their pleas for help. Responding to this extraordinary request demonstrates our commitment to provide this essential medicine to some of the world's most vulnerable people," said Howard Weisman, CEO of PaxMedica.

To view the full press release, visit https://ibn.fm/pEEzW

PaxMedica Inc. (NASDAQ: PXMD) is a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic therapies (APTs) for the treatment of Autism Spectrum Disorder (ASD) and other serious conditions with intractable neurologic symptoms.

The company’s lead programs are focused on ASD, for which there are currently no approved pharmacologic treatments that target its cause and symptoms. Currently used treatments only address the symptoms of the condition, rather than targeting the pathophysiology itself.

PaxMedica is on a promising path to address these unmet medical needs, bringing hope to millions. Anti-purinergic therapies target the excess production of purines in cells. An overexpression of purines can offset homeostasis and result in an overproduction of cellular adenosine triphosphate, the main energy molecule in all living cells.

The company is headquartered in Tarrytown, New York.

Product Pipeline

PaxMedica is building a robust pipeline of products targeting ASD and related neurodevelopmental conditions. The company’s lead product in development may help eliminate, reduce or modulate some of the more troublesome aspects of ASD. That would open the potential for people with autism to integrate their behavior with others more successfully and improve their lives.

PaxMedica’s lead programs, PAX-101 and PAX-102, utilize the company’s proprietary source of suramin sodium, a broadly acting anti-purinergic therapy that has been known for over 100 years. Its current pipeline includes:

  • PAX-101 (IV Suramin) for ASD – PAX-101 completed a Phase 2B study for ASD in 2021. Suramin is a broadly acting APT and has reported positive results from a dose range study. The results of PaxMedica’s Phase 2B study, which targeted 52 subjects across six sites in South Africa, were presented to AACAP in October 2021.
  • PAX-102 (Intranasal Suramin) – PaxMedica has developed a proprietary intranasal formulation of suramin that is currently being evaluated in ASD and other neurodevelopmental conditions.
  • PAX-101 for HAT – Given suramin’s historical use as a treatment for Human African Trypanosomiasis (HAT), or African Sleeping Sickness, the company is also developing PAX-101 as a treatment for HAT. PaxMedica’s most advanced program is the pursuit of PAX-101 for early-stage East African HAT.
  • Selective APTs – PaxMedica has conducted several preclinical studies to evaluate other APTs that are more selective to specific purinergic receptors and may offer additional benefits over suramin.

Market Opportunity

According to a report by Fortune Business Insights, a leading global market research company, the global ASD therapeutics market was estimated at $1.93 billion in 2022 and is projected to grow from $2.01 billion in 2023 to $3.42 billion by 2030, a CAGR of 7.9% over the forecast period. As there is no current treatment for the core symptoms of autism, PaxMedica believes the addressable market for PAX-101, if approved, could greatly exceed these forecasts.

Autistic disorder, Asperger’s Syndrome and Pervasive Development Disorder are the three main types of ASD, affecting millions of people globally. A 2020 report by the U.S. Centers for Disease Control & Prevention estimated that one in 36 children in the U.S. have been diagnosed with autism disorder.

Several factors are expected to contribute to market growth prospects. A growing prevalence of the condition globally and rising awareness coupled with available treatment options are key factors expected to drive ASD therapeutics market growth during the forecast period. Growing investment in R&D to find effective treatments is also expected to fuel global market growth.

Management Team

Howard Weisman is Chairman and CEO of PaxMedica. He has been a founder and CEO of several specialty pharma and medical device companies. Most recently, he was executive chairman and co-founder of Sofregen, a biotech company. He also served as CEO and president of Seventh Sense Biosystems, a medical device development company. He also was founder, chairman and CEO of EKR Therapeutics, a specialty pharmaceutical company, and founder and COO of ESP Pharma, a company focused on cardio and neurovascular products. He has a bachelor’s degree in chemistry from Rutgers University.

David Hough, M.D., is Chief Medical Officer at PaxMedica. He is a neuroscience clinical development consultant who previously served as vice president at Janssen Research and Development and in various leadership roles over 17 years. Most recently, he was the compound development team leader for SPRAVATO® for treatment-resistant depression. Prior to that, he was the schizophrenia disease area leader. He played a pivotal role in the development programs for oral INVEGA®, INVEGA SUSTENNA® and XEPLION® for schizophrenia. He is a graduate of West Point and is board certified in psychiatry.

Stephen Sheldon is COO and CFO at PaxMedica. He has served as CEO of Thailand-based specialty healthcare company Indochina Healthcare Co. Ltd. since 2015. Previously, he was a consultant for PricewaterhouseCoopers Healthcare Advisory in the Chicago office. He was responsible for developing specialty pharmacy patient programs, strategy development for specialty products and compliance programs. He has an MBA from Thunderbird School of Global Management and a bachelor’s degree in computer science and visual arts from Bowdoin College.

PaxMedica Inc. (NASDAQ: PXMD), closed Tuesday's trading session at $0.2199, up 4.7143%, on 1,478 volume. The average volume for the last 3 months is 9.148M and the stock's 52-week low/high is $0.20/$10.26.

Recent News

SOBRsafe Inc. (NASDAQ: SOBR)

The QualityStocks Daily Newsletter would like to spotlightFathom SOBRsafe Inc. (NASDAQ: SOBR).

Transdermal alcohol detection solutions provider SOBRsafe is implementing strategies to further strengthen its financial position

During Q2 2024, the company eliminated $2.6 million in debt and improved its balance sheet with a capital infusion from the exercise of warrants

SOBRsafe has increased its revenue by 44% from Q2 2023 as it continues to onboard new customers in 2024

SOBRsafe (NASDAQ: SOBR), the provider of next-generation transdermal alcohol detection solutions, has continued to implement plans and strategies to strengthen its financial position and restructure shareholder equity throughout the second quarter of its 2024 financial year, according to its recent Q2 2024 quarterly update (https://ibn.fm/ZWPa8).

SOBRsafe Inc. (NASDAQ: SOBR) is a provider of a game-changing transdermal (touch-based) alcohol detection technology that can improve workplace safety and provides advanced screening and monitoring solutions for the behavioral health industry.

Alcohol misuse is the fourth leading cause of preventable death in the U.S., and the seventh worldwide. Nearly half of all industrial accidents with injuries are alcohol-related, and 1-in-10 U.S. commercial drivers tests positive for alcohol – the highest rate in the world. Despite these statistics, prevention and monitoring solutions have not kept pace with this epidemic. Legacy detection technologies are invasive and inefficient, unhygienic and unconnected. SOBRsafe believes there is a better way.

The company has developed a patent-pending alcohol detection device called SOBRcheck™ for use in detecting alcohol in humans, with just the touch of a finger. SOBRsafe’s next-generation transdermal technology detects and instantaneously reports the presence of alcohol as emitted through a user’s skin. No breath, blood or urine sample is required. SOBRsafe believes its technology is a superior, hygienic alternative to traditional breathalyzers for frontline, preventative applications.

With a powerful backend data platform, SOBRsafe provides humane, passive and connected alcohol detection for the behavioral health, transportation, oil and gas, judicial and consumer markets.

A preventative solution in historically reactive industries, SOBRsafe technology is being deployed for commercial fleets, workplaces, alcohol rehabilitation, probation management and teen drivers. This monitoring technology helps prevent intoxicated workers from taking the factory floor or drivers from receiving the keys to a truck, bus or family car. An offender is immediately flagged, and an administrator is empowered to take the appropriate corrective actions.

SOBRsafe technology is commercially available for access control (SOBRcheck), wearable use (SOBRsure™) and licensing or white labeling.

The company is headquartered in the Denver (CO) Technology Center.

Products

The SOBRsafe technology is integrated within the company’s robust and scalable data platform, producing statistical and measurable user and business data.

SOBRsafe™

With a mission is to save lives, increase productivity, create significant economic benefits and positively impact behavior, SOBRsafe developed the scalable, patent-pending SOBRsafe™ platform for non-invasive alcohol detection, real-time reporting and historical data aggregation.

SOBRsafe is a solution that has broad applications in behavioral health, fleet and facility safety, youth drivers and judicial markets.

SOBRcheck™

SOBRcheck is the company’s stationary identification and alcohol monitoring product, providing a quick, specific-point-in-time test for the presence of alcohol. In hygienic, real-time fashion, SOBRcheck verifies user identity and determines the absence or presence of alcohol.

SOBRcheck provides an administrator immediate results – delivered securely – to aid in the efficient management of an existing substance abuse policy.

SOBRsure™

SOBRsure is the company’s transdermal, alcohol-detecting wearable. SOBRsure provides continuous, mobile alcohol monitoring. The band’s advanced alcohol safety technology discreetly detects and instantaneously reports the presence of alcohol in the body. Additionally, SOBRsure provides app-based alcohol detection alerts, pinpoint location tracking and band-removal notifications.

The SOBRcheck and SOBRsure revenue models consist of two components: (1) a hardware device purchase and (2) a recurring monthly SaaS subscription fee.

Design, manufacturing, quality testing and distribution for all SOBRsafe devices takes place in the U.S.

 

Market Opportunity

A report from Data Bridge Market Research, an international market research and consulting firm, estimated the global alcohol sensor market at $2.3 billion in 2022. The market is forecast to reach a value of $6.3 billion by 2030, recording a CAGR of 13.7% over the forecast period.

Market growth drivers, as cited by the report, include rising alcohol consumption rates, more stringent laws pertaining to alcohol consumption and new, more effective technologies that facilitate detection and enforcement.

Greater awareness of alcohol consumption as a potential threat to public and workplace safety has led to increased emphasis on preventing operation of motor vehicles and machinery by those under the influence of alcohol and promoting responsible alcohol consumption, as the report details.

Management Team

David Gandini is Chairman and CEO of SOBRsafe. He most recently served as president of IPS Denver, a bank card personalization company. Prior to that, Dave was the COO at First World Communications, a U.S. internet and data center provider, and participated in its successful IPO. He previously founded Pace Network Services and facilitated a successful exit to ICG Communications. Dave also co-founded Detroit-based Digital Signal in the fiber optic long haul market sector, where he executed a successful exit to SP Telecom.

Chris Whitaker, CPA, is CFO of SOBRsafe. Previously, Chris had served as the Company’s Vice President of Finance and Accounting. He has held various executive finance positions with large public multi-national corporations and small entrepreneurial companies throughout a progressive 30-year career that began with KPMG. Chris was formerly President – Americas and Vice President of Finance and Administration for public, multinational corporation Elixinol. He also served as the Managing Director of AEGIS Financial Consulting, leading a team of consultants in providing fractional CFO and financial consulting services to a wide variety of businesses in the public and private sectors.

Scott Bennett is EVP, Business Operations at SOBRsafe. He has more than 20 years of experience as a senior executive in technology-driven enterprises. Prior to joining SOBRsafe, he co-founded cybersecurity firm GBprotect and served as its COO until its successful sale to Nuspire. He previously served as Chief Technical Officer/Chief Information Security Officer of fintech businesses Catalyst Card Company and Integrated Printing Solutions.

SOBRsafe Inc. (NASDAQ: SOBR), closed Tuesday's trading session at $0.1123, up 2.7447%, on 1,434,427 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $10.26/$.

Recent News

FuelPositive Corp. (TSX.V: NHHH) (OTC: NHHHF)

The QualityStocks Daily Newsletter would like to spotlight FuelPositive Corp. (NHHHF).

FuelPositive (TSX.V: NHHH) (OTCQB: NHHHF), a leading green ammonia company, has released a status update. According to the announcement, the update outlines the company's significant milestones as it "closes in on system activation and broadens its network of strategic partners." The report includes highlights from FuelPositive's Aug. 19, 2024, finance meeting with Adrien Sala; a project timeline update; the company's initiative to strengthen the team, promote excellence and address challenges; recent financing developments and sales efforts; and the expansion of strategic networks.

"As the company approaches critical milestones, FuelPositive is entering an exciting phase of growth and innovation," said the company in the press release. "With the continued support of . . . stakeholders, strategic partners and a strengthened team, FuelPositive is well-positioned to revolutionize the agricultural industry with the company's green ammonia technology. The momentum FuelPositive has built through its recent achievements sets the stage for a future filled with transformative possibilities."

To view the full press release, visit https://ibn.fm/jZ8Hf

FuelPositive Corp. (TSX.V: NHHH) (OTC: NHHHF) is a growth stage company focused on licensing, partnership and acquisition opportunities building upon various technological achievements. The company is committed to providing commercially viable and sustainable clean energy solutions, including carbon-free ammonia (NH3), for use across a broad spectrum of industries and applications.

FuelPositive is headquartered in Toronto, Canada.

Hydrogen Economy Problems and FuelPositive’s Carbon-Free Technology

The hydrogen economy is currently facing many challenges. Traditional NH3 manufacturing exists on a massive scale, but centralized facilities result in some of the world’s most concentrated CO2 emissions. In total, an estimated 200 million metric tonnes of NH3 are consumed each year, with greater than 80% utilized by the agricultural sector. NH3 is also being positioned as a viable alternative to fossil fuels.

FuelPositive’s flagship carbon-free ammonia technology provides an innovative solution to these environmental concerns. Developed by Dr. Ibrahim Dincer and his team, the company’s platform allows for the in-situ production of NH3 in an entirely sustainable manner, using only water, air and sustainable electricity.

The production of hydrogen is energy intensive, but it is just one variable hindering the growth of the hydrogen economy. Other hurdles include:

  • Storage – The storage of hydrogen by compression or liquification are both cost prohibitive and unsustainable.
  • Distribution – The distribution network for effective hydrogen deployment has yet to be developed, as the extreme high-pressure distribution requirements to transport hydrogen would result in enormous infrastructure costs.
  • End Use – R&D on the transportation-related end use applications for hydrogen is in its infancy, but almost any vehicle on the road today can be easily converted to run on NH3 at a considerably lower cost per mile traveled when compared to traditional fossil fuels.

A key benefit of FuelPositive’s patent-pending, first-of-its-kind carbon-free NH3 technology is its flexibility. The process allows for small, medium or large-scale production of NH3 on location, minimizing or even eliminating the challenges and volatility associated with storage and transportation to end use. As such, with an appropriately sized FuelPositive system and access to renewable energy, the end use applications for the company’s platform are nearly infinite.

Manufacturing Partnership

On May 19, 2021, FuelPositive announced its selection of National Compressed Air Canada Ltd. (“NCA”) to undertake manufacturing of the company’s Phase 2 hydrogen-ammonia synthesizer commercial prototype systems for carbon-free ammonia production.

In a news release detailing the partnership, FuelPositive CEO Ian Clifford noted, “This critical milestone for FuelPositive will confirm the broad application potential for our technology and is the backbone of our Carbon-Free Hydrogen-NH3 offering. Partnering with the knowledgeable and experienced team at NCA on this commercialization project will bring our development-stage program to life.”

Global Ammonia Market Outlook

The global ammonia market was valued at $52.71 billion in 2017 and is forecast to reach $81.42 billion by 2025, growing at a CAGR of 5.59%, according to data from Fior Markets (https://ibn.fm/1OfOB).

The agricultural industry consumes more than 80% of global NH3. Smaller percentages can be attributed to the waste, water treatment, refrigerants, antiseptic, textile, mining and pharmaceutical industries.

One of the most polluting industries on the planet consists of conventional agribusinesses. These polluters are responsible for more greenhouse emissions per year than transportation. This is where FuelPositive’s technology is expected to be extremely beneficial.

Management Team

Ian Clifford is Director, CEO and Founder of FuelPositive Corp. He has over 25 years of experience in the fields of technology and marketing and has successfully led the company to global brand recognition through its unique energy solutions. Since 2006, Mr. Clifford has raised over $50 million in equity financing for FuelPositive. He also co-founded digIT Interactive, a full-service internet marketing company serving Fortune 500 clients, which he sold at the peak of the market in 2000.

Greg Gooch serves as a Director and President of FuelPositive. His multifaceted career in the electronics and finance industries has positioned him as a key advisor and funding partner to start-ups and new technology companies for over 40 years. Mr. Gooch has been involved with FuelPositive since its early days and has remained a significant supporter and consultant to the company over the years. He has a bachelor’s from McGill University and an MBA from the University of Western Ontario.

Dr. Ibrahim Dincer is a scientific advisor to FuelPositive and is recognized as a pioneer and international leader in the area of sustainable energy technologies. Along with his team, Dr. Dincer invented the modular carbon-free ammonia (NH3) production technology that FuelPositive is commercializing. His area of specialty covers various topics including ammonia, hydrogen energy and fuel cells; renewable energy systems; energy storage systems and applications; carbon capturing technologies, and integrated and hybrid energy systems He is currently managing an exemplary team of researchers in this commercialization project.

Marek Warunkiewicz is the company’s Communications & Branding Specialist. He brings more than 40 years of entrepreneurial expertise to the FuelPositive team, having held marketing, branding, advertising, project management and graphic design positions with various companies. Mr. Warunkiewicz has successfully created business-to-business marketing and advertising campaigns for a diverse group of clients ranging from high-tech to agriculture. He co-founded digIT Interactive and ZENN Motor Company alongside Ian Clifford.

Luna Clifford is the Director of Communications for FuelPositive. She has over 10 years of experience as a business owner and advisor, helping build and operate several successful start-up enterprises while managing complex stakeholder relationships. Ms. Clifford excels in strategic planning and team building, and she has completed extensive studies in the fields of communications and health care.

FuelPositive Corp. (NHHHF), closed Tuesday's trading session at $0.033, up 33.3333%, on 2,019,578 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.0221/$0.07.

Recent News

GEMXX Corp. (OTC: GEMZ)

The QualityStocks Daily Newsletter would like to spotlight GEMXX Corp. (OTC: GEMZ) .

This week saw the price of gold extend its run, remaining above $2,500, driven by increasing investor confidence that the Fed will likely reduce rates of interest next month, and a weaker dollar. Specifically, the price of spot gold hit $2,510.32 an ounce, representing a 0.3% increase. This comes after recording a new high of $2,531.60 per ounce. U.S. gold futures also rose 0.4% to hit $2550.60 per ounce. On the other hand, the dollar index dipped to a seven-month low, which made gold more attractive for holders of other currencies. At the same time, benchmark United States 10-year bond yields also dropped. Other metals didn't perform as well as gold, with the price of palladium dropping to $927 an ounce, which represents a 0.5% drop. Platinum and spot silver also recorded decreases in prices, falling to $949.05 and $29.42 respectively. As the price of gold continues on its upward trajectory, the profit margins of jewelry makers may get squeezed by the higher cost of inputs. However, this pressure could be minimal for jewelry makers that don't buy gold on the open market, such as GEMXX Corp. (OTC: GEMZ); rather these companies are involved in its extraction and other processes until the precious metal is used to make jewelry.

GEMXX Corp. (OTC: GEMZ) is a mine-to-market enterprise specializing in gold, gemstone, and jewelry production. With ownership of mining resources, production facilities, and operational assets, the company maintains control over every aspect of its production process, from gold mining and gemstone extraction to jewelry manufacturing and global distribution.

As a prominent player in the industry, GEMXX stands out as a leading producer of high-quality finished Ammolite jewelry. Notably, it holds the distinction of being the sole public company engaged in Ammolite mining worldwide. In addition to its Ammolite operations, the company is actively involved in gold mining and prides itself on its ability to design and manufacture exquisite jewelry pieces and exceptionally rare, natural fossil decor items for clientele around the globe.

One of GEMXX’s key advantages lies in mining its own gold reserves to be utilized in its jewelry production. This strategic approach provides the company with a cost-saving edge over other producers in the market.

Ammolite is similar to black opal and is a biogenic gem like amber and pearl. It is derived from the fossilized shells of ammonites, a group of extinct marine nautiluses.

GEMXX’s world class gemstone cutters and jewelry designers are continuously leading the Ammolite industry. Its team believes in the company’s philosophy, vision and goals, and works every day to continue to drive the Ammolite industry to the forefront of the gem world.

The company has offices in Las Vegas and Hong Kong.

Projects and Operations

GEMXX has formulated an ambitious growth plan that, while challenging, is deemed attainable. The company’s strategy revolves around bolstering its market share through several key initiatives. Firstly, GEMXX aims to strengthen its position in current markets by nurturing and expanding existing relationships with customers and partners.

Secondly, the company plans to venture into untapped markets strategically. By identifying and targeting new areas, GEMXX seeks to establish a presence in regions that present promising opportunities for growth.

Additionally, GEMXX envisions growth through acquisitions. By considering and integrating key services, distribution networks and retail outlets into its fold, the company aims to consolidate its market position and capitalize on synergies for enhanced success.

To cater to the rising demand for its products, GEMXX has placed a primary focus on increasing gemstone production. The company’s southern properties, situated in Alberta, Canada, hold valuable deposits of rough Ammolite gemstone. By tapping into these resources, GEMXX is poised to meet the demand for its exquisite gemstone products and further fuel its expansion plans.

 

GEMXX possesses significant mineral assets in the form of a Mineral Work Permit covering an 800-acre area and two Ammonite Shell Mineral agreements encompassing 217 acres within the same region. The company’s management effectively operated mines in close proximity to these properties. Moreover, core sampling, along with fossil outcroppings on the riverbanks, confirms a substantial Ammolite resource present in these designated areas.

Both the Mineral Work Permit and the Ammonite Shell Mineral agreements grant GEMXX unrestricted access to all Ammolite resources within their respective demarcations. Notably, the company is not obligated to pay any royalties to third parties, thereby enabling GEMXX to fully capitalize on the potential of these valuable resources.

Furthermore, there are no stringent regulatory conditions that GEMXX must fulfill to gain or retain access to the Ammolite deposits. This freedom of access allows the company to proceed with its mining and production operations unimpeded, providing an advantageous position for future growth and success.

In March 2023, GEMXX made a significant announcement, revealing its acquisition of a 50% ownership stake in Crazy Horse Mining Inc., a Canadian gold mining company with assets situated in the province of British Columbia. As part of this deal, Crazy Horse’s assets, which encompass a 100% interest in two gold projects, called Snow Creek and Rosella Creek, spread across a substantial area exceeding 700 acres, now become part of GEMXX’s portfolio.

Under the terms of this strategic partnership, GEMXX and Crazy Horse will jointly share the expenses related to mining operations on these projects. Additionally, the two companies will share the gold produced from these ventures, leading to a collaborative and mutually beneficial arrangement.

Initial tests conducted on the property, combined with gold already recovered this season, confirm all expectations for the claims and substantiate the company’s estimated extraction target of over 100,000 ounces of easily recoverable gold. To validate and provide a more comprehensive assessment of this estimate, an S-K 1300-compliant Resource Report is scheduled to be conducted during the summer of 2023.

By acquiring this stake in Crazy Horse Mining Inc., GEMXX has positioned itself for further growth in the gold mining sector and is poised to capitalize on cost of goods savings in its jewelry business.

Market Opportunity

Leading independent market research companies such as Data Monitor and GIA estimate the worldwide market for luxury or premium lifestyle products, which include gems and jewelry, at over $90 billion annually and growing. Ammolite sales around the world have seen unprecedented growth over the past 20 years. Worldwide retail sales are now estimated to be over $100 million.

Ammolite jewelry and fossils are featured aboard cruise ships and can be found in specialty shops in almost every cruise port in North America. Asian markets have grown since feng shui master Edward Li called Ammolite the most influential stone of the new millennium, referring to it as the “Seven Color Prosperity Stone.” Home shopping channels in Japan, Australia, France, Germany, the UK, Canada and the U.S. have all featured Ammolite jewelry.

Ammolite and ammonites can also be found on many ecommerce sales platforms, including Amazon, eBay and Etsy. Ammolite is sold around the world in tourist and traditional jewelry markets. The company has established customers in home shopping channels, cruise tourism, jewelry retailers, Asian feng shui markets, Asian retail markets and ecommerce platforms.

Management Team

With over 160 years in Ammolite management, operations, and sales, GEMXX possesses an unparalleled wealth of knowledge and expertise. Its team members have extensive backgrounds in every facet of the Ammolite business, allowing the company to excel in product development, maintain rigorous quality control measures, and maximize profitability. The breadth and depth of the GEMXX team’s experience enable the company to navigate the industry with precision, ensuring that GEMXX remains at the forefront of the Ammolite market. GEMXX leverages its collective wisdom to drive innovation, deliver exceptional products, and optimize business strategies to achieve long-term success.

Jay Maull is Founder, CEO and Chairman of GEMXX. With a career spanning more than three decades, he has been deeply involved in the Ammolite industry, from mining and production to marketing. He has owned and operated the world’s largest Ammolite mine and has delivered exceptional Ammolite products to customers across all continents. He has also established the world’s largest Ammolite ecommerce platform.

Richard Clowater is President of GEMXX. He is a skilled sales and marketing professional with a focus on research, data analysis and strategic planning. He has successfully implemented initiatives to expand markets, boost profits and foster customer loyalty. He has an impressive track record of negotiating sales and contracts worth over $250 million with influential stakeholders, including key purchasing personnel, C-suite executives and government entities at all levels.

Tom Dryden is a Vice President of GEMXX and brings a wealth of experience and expertise to the production and marketing of Ammolite, spanning over 30 years. His extensive involvement in the industry has granted him unparalleled knowledge of the Bearpaw Ammonite bearing formations. As a recognized authority in the field, Mr. Dryden’s research and papers on Canadian Ammonites have garnered global recognition, being published worldwide. In his role at GEMXX, Mr. Dryden assumes the responsibility of overseeing the company’s Canadian-based production facilities. 

P. K. Chung is Business Manager Asia at GEMXX. With a track record of over 25 years in Ammolite business management, production and marketing in Asia, she is a recognized authority in the industry. Based in the Hong Kong gem district, she possesses an intricate understanding of the Asian gem and jewelry markets, including market dynamics, consumer preferences and industry trends specific to the region. Her strategic insights and deep connections enable GEMXX to thrive in this influential market.

GEMXX Corp. (OTC: GEMZ), closed Tuesday's trading session at $0.0163, up 30.4%, on 1,000 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.0125/$0.1195.

Recent News

NextPlat Corp. (NASDAQ: NXPL) (NASDAQ: NXPLW)

The QualityStocks Daily Newsletter would like to spotlight NextPlat Corp. (NASDAQ: NXPL) (NASDAQ: NXPLW).

Artificial intelligence (AI) seems to be making a mark on different industries, with some companies even recording growth in the healthcare and retail sectors. These companies are using artificial intelligence to address issues in these sectors, from rising medical bills to sizing issues in e-commerce. This indicates a possible shift in how industries are approaching different problems. One provider of AI-driven measurement solutions for e-commerce, MySize Inc., announced strong results from its second quarter. The company recorded a 53% increase in its revenues, driven primarily by its sizing tech and e-commerce platform powered by artificial intelligence. It also saw its gross profits rise significantly to reach $984,000, which reflects the higher margins links to its SaaS offerings powered by AI. This funding comes as hospitals and patients alike grapple with increasing medical costs. With this cash influx, PayZen remains focused on developing new artificial intelligence tools to address affordability in the healthcare sector while reaching more patients. As AI startups bring to market innovative solutions that address real needs, these companies are likely to make further inroads in the segments they target given the pointers already shown by enterprises such as NextPlat Corp. (NASDAQ: NXPL) (NASDAQ: NXPLW) that businesses are willing to incorporate AI solutions which can help serve their customers better.

NextPlat Corp. (NASDAQ: NXPL) (NASDAQ: NXPLW), a next generation e-commerce platform, was created with vision and purpose to capitalize on high growth sectors and global markets. The company collaborates with businesses – large and small – to simplify and accelerate online commerce and uniquely enables customers and partners to optimize their e-commerce reach, presence and revenue. NextPlat recently launched a new e-commerce development program to provide American businesses with easy access to the massive Chinese consumer market.

Current Initiatives

NextPlat provides cutting edge technology in an advanced e-commerce ecosystem. The company is actively expanding its global network of online storefronts serving thousands of consumers, enterprises and governments. The company also has developed a next generation platform built for Web3 that enables the creation and sale of digital assets, as well as optimizing e-commerce transactions and business building activities. The company’s current initiatives include:

  • E-Commerce Development Program – In April 2023, NextPlat announced it had entered into a merchant sourcing agreement with Alibaba.com Singapore E-Commerce Private Limited (“Alibaba”) and its Tmall Global e-commerce platform whereby the two companies will collaborate to increase the sale of products produced and sold by American companies to the multi-trillion-dollar Chinese consumer market. Alibaba’s Tmall Global e-commerce platform will provide NextPlat customers a turn-key solution through which products can be sold to the Chinese consumer market. The launch of the Florida E-Commerce Development Program is the first in a series of new NextPlat programs designed to assist U.S. businesses in expanding their online sales capabilities to reach new international customers in the Chinese market. NextPlat intends to rapidly expand this unique e-commerce development opportunity to businesses throughout the United States and all of North America, as well as Central and South America. The new development program features NextPlat’s turnkey global e-commerce solution for customers and leverages NextPlat’s relationships with key partners, including Tmall Global, China’s largest cross-border B2C online marketplace.
  • Progressive Care Inc. – In August 2022, NextPlat completed a strategic $7 million investment in Progressive Care Inc. (OTCQB: RXMD), a personalized health care services and technology company. In a news release announcing the investment, NextPlat CEO Charles M. Fernandez noted that the company is “committed to harnessing the power of digital technologies to capitalize on the ongoing digital transformation of Progressive Care and the entire health care industry.” NextPlat intends to accelerate Progressive Care’s digital health care transformation with the launch of a new e-commerce platform for health care products later this year.
  • NextPlat NFT Platform – Building on its existing e-commerce initiatives, NextPlat is working to bridge the gap between tangible and digital e-commerce marketplaces by incorporating burgeoning Web3 technologies. The company intends to launch a fully integrated NFT platform in the coming months that will enable brands to create, manage and authenticate digital assets while serving as a new source of revenue for NextPlat. Through this model, the company will receive a portion of the revenue generated from branded NFT drops, as well as subsequent secondary market transactions.
  • Global Telesat Communications and Orbital SatCom Corp. – Targeting both domestic and international markets, NextPlat’s subsidiaries leverage partnerships with major e-commerce platforms such as Amazon, Alibaba, eBay and Walmart to serve a growing base that includes more than 50,000 corporate, governmental and individual customers. In total, the brands market more than 10,000 individual products, with a focus on satellite-based connectivity solutions. In addition to exploring accretive M&A opportunities, NextPlat aims to diversify its range of products and broaden its geographic footprint moving forward in an effort to better capitalize on the tremendous growth potential in the United States, Europe and Asia.

“Our goal for 2023 and beyond is to leverage our improved operational capabilities and enhanced leadership team as we expand our offerings in communications and connectivity into the high-growth health care market where we intend to launch an array of innovative new offerings,” Fernandez said in a March 2023 news release detailing the company’s record top-line performance. “Although there remain supply chain headwinds and the challenge of global inflation, we are confident that we have the right combination of market-tested expertise, technology and partnerships that will enable us to bring the power of e-commerce to more customers, brands and industries in the United States and abroad.”

Market Opportunity

The rapid growth of e-commerce over the last decade is expected to continue for the foreseeable future. According to data published by Forbes, roughly 20.8% of all retail purchases are expected to take place online in 2023, accounting for total sales of $6.31 trillion worldwide. It total, e-commerce sales are expected to grow by 10.4% YoY in 2023, accounting for a whopping 24% of all retail purchases by 2026.

For NextPlat, existing partnerships in the industry could be key to capitalizing on this growth. The Forbes report indicates that Amazon accounts for roughly 38.7% of e-commerce sales, while sites like Walmart, eBay and Alibaba round out the list of most visited e-commerce websites. Alibaba is especially interesting due to NextPlat’s recent strategic merchant sourcing agreement with Tmall Global. The Chinese market is “mammoth,” as a recent Alizila report noted. The country’s annual online retail sales of physical goods have nearly doubled in the last five years, reaching approximately 13.8 trillion yuan in 2022, which is nearly $2 trillion USD.

The health care portion of the e-commerce market is generating particularly bullish forecasts, bolstered by the continued adoption of the 340B Drug Pricing Program in the U.S., which requires most drug manufacturers to provide outpatient drugs to covered entities at significantly reduced prices. Industry reports suggest that the global health care e-commerce market will expand at a compound annual growth rate of 16.8% from 2022 to 2030, climbing to a value of more than $1.37 trillion by the end of the forecast period.

Management Team

Charles M. Fernandez, CEO, Executive Chairman and Director of NextPlat, has over three decades of experience in identifying profitable start-up and dislocation opportunities, building significant value and executing exit strategies as an entrepreneur and global investor. Successful across multiple sectors, Fortune Magazine actually labeled Fernandez ‘a restructuring whiz’. As President of Fairholme Capital Management, which he joined in 2008, Mr. Fernandez co-managed all three Fairholme funds and brought in a $2 billion gain for shareholders. Throughout his impressive career, he has participated in more than 100 significant mergers, acquisitions and product development projects across multiple industries. Mr. Fernandez was the founder, Chairman and CEO of eApeiron Solutions LLC, a brand protection and e-commerce company in partnership with Alibaba (NYSE: BABA) and Eastman Kodak (NYSE: KODK), which was successfully sold to Smartrac, a unit of Avery Dennison Corp. (NYSE: AVY).

Rodney Barreto is Chairman and CEO of the Barreto Group and Director of Nextplat. Mr. Barreto’s business career spans over 35 years, including his role at the Barreto Group and, earlier, as the founding partner of Floridian Partners LLC, a corporate and public affairs consulting firm recognized by policy makers as one of the top in its industry in Florida. He chaired the Super Bowl Host Committee in 2007, 2010 and 2020, helping to raise more than $100 million for the success of Miami Super Bowls. As a philanthropist and conservationist, Mr. Barreto is also a three-time appointee to the Florida Fish and Wildlife Conservation Commission, where he has served for over 10 years including holding the title of Chairman eight times. He has twice chaired the Annual U.S. Conference of Mayors, was Chairman of the 1999 Breeder’s Cup Championship held in South Florida and was the Chairman of the 1999 Sister Cities International Convention in Miami. Currently, Mr. Barreto is the Membership Chairman of the Florida Council of 100, and a member of the Boards of Fairchild Tropical Botanic Garden, the Baptist Health South Florida Giving Society, the Bonefish and Tarpon Trust, the Guy Harvey Ocean Foundation, and a member of Miami Dade County Schools Superintendent Carvalho’s Business Advisory Council. Prior to his career in public affairs and real estate, Mr. Barreto was a City of Miami police officer and is a member of the Florida Highway Patrol Advisory Council.

NextPlat Corp. (NXPL), closed Tuesday's trading session at $1.23, even for the day, on 56,472 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.9857/$2.68.

Recent News

Torr Metals Inc. (TSX.V: TMET)

The QualityStocks Daily Newsletter would like to spotlightFathom Torr Metals Inc. (TSX.V: TMET) .

Torr Metals is establishing itself as a key player in Canada's booming mining industry, a global leader in the production of over a dozen essential metals

The company's emphasis on early-stage district-scale copper and gold projects underscores a significant ground floor opportunity and growth potential within the sector

Building on early successes by leveraging historical data to expand known mineralization trends, Torr Metals is strategically positioned for potential major new discoveries at Kolos, Filion, and Latham, all within close proximity to established provincial and mining infrastructure

Canada has long been a global leader in the mining industry. Its vast, mineral-rich land, coupled with a stable political and economic climate, has fostered a thriving mining sector. Canada is the 4th largest global gold and 12th copper producer, while also ranking the among the top five producers of aluminum, cobalt, diamonds, fluorspar, gemstones, gold, indium, niobium, palladium, platinum, tellurium, titanium concentrate and uranium. This type of dominance would not be possible without world-class mining expertise, environmental, social and governance ("ESG") standards, and infrastructure. This combination of factors has positioned the country as a favored destination for mining investment, with nearly half of the world's publicly listed mining and mineral exploration companies based in the country. Torr Metals (TSX.V: TMET) is emerging as a key player in Canada's mining sector, with a strong focus on early-stage discovery potential that could unlock significant value. Headquartered in Vancouver, British Columbia, Torr is dedicated to advancing its 100% owned, district-scale projects in highly accessible and mineral-rich regions across Canada. These projects are not only poised to contribute to the clean energy revolution with critical minerals like copper but also offer the added economic benefit of potential new major gold discoveries. With existing infrastructure, year-round drilling potential, and low-cost development opportunities, Torr Metals is strategically positioned to capitalize on its exploration successes.

Torr Metals (TSX.V: TMET), a mineral exploration company focusing on the identification, acquisition and advancement of mineral properties, is reporting on the final assay results from a total of 33 rock grab samples collected during 2024 reconnaissance programs. According to the report, the samples reveal additional high-grade rock grab assays within the Kirby, Rea and Clapperton exploration target zones as well as a new copper-gold discovery in the northern portion of the Kolos Copper-Gold Project, which is now called the Sonic Zone.

"The latest results from our 2024 reconnaissance sampling programs not only reaffirm the high-grade potential of the Kolos Project but also highlight significant untapped exploration opportunities across multiple zones," said Torr Metals president and CEO Malcolm Dorsey in the press release. "The discovery of the Sonic Zone is particularly promising, as it opens up a new area of mineralization that bears geological similarities to the high-grade New Afton copper-gold porphyry deposit, located just 27 kilometers to the north. These findings underscore the vast potential for untouched new discoveries within the project area, and as we advance into the 2024 field season, we anticipate delivering substantial value to our shareholders through continued exploration of these exciting new targets as well as development of our already established zones."

To view the full press release, visit https://ibn.fm/jsk8O

Torr Metals Inc. (TSX.V: TMET) operates as a mineral exploration company focusing on the identification, acquisition, and advancement of mineral properties. With full 100% ownership of over 1,000 square kilometers of gold and copper projects strategically positioned in premier low-cost mining jurisdictions, Torr is poised for substantial returns across various promising regions.

The company’s extensive portfolio encompasses multiple district-scale projects, including the Filion Gold Project in northern Ontario, the Kolos Copper-Gold Project in south-central British Columbia, and the Latham Copper-Gold Project in northern British Columbia. These projects are all located in prolific mining regions with paved highway access, robust support infrastructure, and favorable geological conditions offering significant potential for new discoveries.

Headquartered in Vancouver, British Columbia, Torr Metals is ideally situated to leverage its expertise and resources for continued exploration and growth.

Projects

Kolos Copper-Gold Project

Situated within British Columbia’s prime copper-producing belt, the 140-square-kilometer Kolos Copper-Gold Project exhibits Nicola Belt geology similar to notable porphyry mines, including Copper Mountain and Highland Valley, respectively situated 106 kilometers to the south and 30 kilometers to the northwest.

With field operations based in the nearby city of Merritt and year-round access provided via Highway 5, the Kolos Project showcases substantial discovery upside potential with five defined large-scale copper-gold-molybdenum anomalies untested by drilling.

Torr Metals’ primary focus lies in unlocking the potential for major new discoveries at the Kolos Copper-Gold Project, with recent surface geochemical results marking a significant milestone positioning the company as a new key player in the region.

Filion Gold Project

The 261-square-kilometer Filion Project is situated within a largely unexplored greenstone belt where gold was initially discovered in the 1930s. With a comparable geological setting to regional orogenic gold deposits and multiple newly identified and undrilled gold trends in surficial geochemistry, the Filion Project holds significant district-scale exploration promise.

The Filion Project benefits from unparalleled infrastructure access, with direct drive-on access from the Trans-Canada Highway, as well as a regional railway and power grid four kilometers to the south. Additionally, the nearby town of Kapuskasing, with a population of 8,300, provides essential support services.

This strategic positioning ensures the Filion Project’s viability for cost-effective, year-round operations in an area poised for untapped discovery potential.

Latham Copper-Gold Project

Situated in British Columbia’s renowned Golden Triangle, the Latham Project spans a vast 689-square-kilometer district, offering immense potential for multiple major discoveries. Accessible year-round via Highway 37, just 20 kilometers south of the town of Dease Lake, the site is strategically located amidst established mining infrastructure, including the active Red Chris mine to the southeast and upcoming major porphyry projects at Schaft Creek and Galore Creek along-trend to the southwest.

Highlighted by the Gnat Pass copper-gold porphyry deposit dating back to the 1960s, the Latham Project presents a compelling opportunity for significant expansion and potential discovery. A non-compliant indicated resource at the Gnat Pass deposit includes 33 million tonnes at 0.39% copper, open beyond 200 meters vertical depth, alongside six drill-ready kilometer-scale copper-gold exploration targets.

Moreover, the Latham Project’s appeal corresponds to the region being an attractive destination for major asset acquisitions and takeovers. Recent transactions within a 40-kilometer radius include Newmont’s 2021 acquisition of the Saddle North copper-gold porphyry deposit for $311 million and Newcrest’s investment in the Red Chris copper-gold porphyry deposit in 2019 for $804 million, underscoring industry acknowledgment of the region’s potential.

Market Opportunity

The World Gold Council, the industry association for the world’s gold producers, estimated in 2023 that the physical financial gold market, which is made up of bars, coins, gold ETFs and central bank reserves, is worth nearly $5 trillion.

The council reports that gold mine production adds approximately 3,500 tons of the precious metal to the world’s supply annually, equivalent to about 2% growth. This historical scarcity and relatively slow production of new supply, as compared to other commodities, is a primary reason gold has retained its value for millennia, according to the council.

Likewise, a report from Acumen Research and Consulting, a global provider of market intelligence and consulting services, valued the global copper market at $304.1 billion in 2022 and forecast that it will reach a market size of $496.8 billion by 2032, growing at a CAGR of 5.1% over the forecast period.

The report identifies a growing demand for copper in the electronics industry, as well as an expanding copper supply due to increasing production from existing mines and the rising number of mine development projects in developing nations, as driving factors in the rising value of the copper market.

Management Team

Malcolm Dorsey, P.Geo., is President, CEO and Director of Torr Metals. He brings over a decade of expertise as a seasoned exploration geologist and project developer, having been pivotal in driving the success of numerous diverse projects across North, Central, and South America. His comprehensive background spans early-stage exploration through to resource development and project acquisitions. His academic credentials include an M.Sc. in Geology and Geophysics from the University of Calgary, where his research characterized the district-scale structural influences affecting copper and gold mineralizing events in western British Columbia. Prior to his current role, he served as Senior Geologist for Benchmark Metals, where his contributions were instrumental in advancing the company’s gold equivalent resource from approximately 80,000 ounces to a maiden resource estimate of 2.92 million ounces.

John Williamson, P. Geol., is Chairman and Director of Torr Metals. He is a mining executive and investor with more than 30 years of experience as a founder, promoter and leader in the formation, financing and operation of private and public companies with exploration and mining interests worldwide. On more than one occasion his team’s efforts have been recognized for excellence by being named to the TSX Venture 50. He holds a B.Sc. in Geology and is a registered Professional Geologist (P.Geol.) with the Association of Professional Engineers and Geoscientists (APEGA) and the Geological Association of Canada.

Torr Metals Inc. (TSX.V: TMET), closed Tuesday's trading session at $28.72, up 0.8073008%, on 2 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $24.01/$31.90.

Recent News

Energy and Water Development Corp. (OTCQB: EAWD)

The QualityStocks Daily Newsletter would like to spotlightFathom Energy and Water Development Corp. (OTCQB: EAWD) .

John Adler, the head of ESG for retirement systems in New York, revealed recently that there had been no withdrawals on environmental, social and governance (ESG) among managers of private markets. In a recent interview, Adler explained that private market managers were focused on strengthening their ESG processes and had already allocated more resources to work on these initiatives. He called to attention the differences between managers of private markets and their public market counterparts, noting that while both sides seemed to be working on ESG, public market managers didn't necessarily announce their moves. This may be because over the last few years, asset managers in the United States have experienced backlash on their ESG initiatives from critics and GOP legislators. Adler's revelations come after three of the five public pensions schemes overseen by the Office of New York City Comptroller committed to achieving net zero by 2040 in 2021. Two years later, two of the companies had given the go-ahead on implementation plans to help meet this objective. The opinions expressed by Adler don't seem to be farfetched when you consider that many individual companies, such as Energy and Water Development Corp. (OTCQB: EAWD) have embraced ESG and are making it an integral part of everything they do.

Energy and Water Development Corp. (OTCQB: EAWD) is a green-tech engineering solutions company focused on delivering water and energy to extreme environments. The company builds water and energy systems out of already existing, proven technologies, utilizing its patent-pending systems configuration and technical know-how to customize solutions to meet clients’ needs. To date, two water systems have been sold and deployed in Mexico and Germany, and the company is working to fulfill additional orders.

Using its patent-pending design, EAWD is working to build and operate off-grid EV charging stations in Germany. The company is a United Nations-accredited vendor and offers design, construction, maintenance and specialty consulting services to private companies, government entities and non-government organizations for the sustainable supply of energy and water.

EAWD focuses on three main aspects of the water and energy business: (1) generation, (2) supply and (3) maintenance. The green tech industry is constantly evolving due to ongoing and increasing water scarcity, as well as increased energy needs in the world. Therefore, the company believes that by designing sustainable and renewable solutions to these problems, EAWD will become an essential component of a rapidly growing industry with many new markets.

EAWD’s approach seeks to assist businesses with the growth and development of their general operations by ensuring the efficient, profitable and sustainable supply and generation of water and energy, allowing its potential customers to focus on their business while adopting strategies of sustainability.

By using the state-of-the-art technological solutions and technologies identified, designed and provided by EAWD and its collaborators, the company believes that its potential clients will be free to focus on the performance of their operations, as well as with the water and energy consumption or generation regulations within their industries.

EAWD is headquartered in Saint Petersburg, Florida, with operations in Germany and Mexico.

Products

In view of the increased worldwide demand for water and energy, EAWD’s business goals are focused on self-sufficient energy-supplied water generation and green energy production. To accomplish this, the company set out to establish an outsourcing green tech platform to commercialize its state-of-the-art technologies while providing engineering and technical consultation services to design the most sustainable technological solutions that can provide water and energy.

The company has sought potential collaboration with green tech research and development centers in Europe and has established its operating subsidiaries in Hamburg, Germany, where EAWD has started to assemble its patent-pending innovative off-grid, self-sufficient energy supply atmosphere water generation (AWG) systems.

EAWD Deutschland and EAWD Logistik operate in Hamburg, Germany, to meet the increasing demands of water and energy generation projects around the world, as well as to operate the solar-powered EAWD Off-Grid EV Charging Stations, EAWD’s newest product.

The company expects to offer sustainable added value to each project it takes on, while generating revenue from the sale of EAWD Off-Grid AWG Systems, EAWD Off-Grid EV Charging Stations, EAWD Off-Grid Power Systems and EAWD Off-Grid Water Purification Systems; royalties from the commercialization of energy and water in certain cases; and licensing of its innovated technologies, along with its engineering, technical consulting and project management services.

EAWD continues to be a development stage company. It presently assembles its EAWD Off-Grid AWG Systems and EAWD Off-Grid EV Charging Stations at its workshop in Germany and outsources most of its engineering and technical services, as well as services relating to the promotion, sale and distribution of its products.

Market Opportunity

According to a report by Allied Market Research, a global market research, consulting and advisory firm, the worldwide green technology and sustainability market was valued at $10.32 billion in 2020 and is projected to reach a value of $74.64 billion by 2030, growing at a CAGR of 21.9% during the forecast period.

A surge in environmental awareness and increasing concerns among organizations and individuals about climate change drive the growth of the market. Furthermore, an increase in consumer and industrial interest for the use of clean energy resources are among some of the major factors expected to boost growth of the market in the coming years, according to the report.

The expected rise in favorable government and private initiatives to tackle climate change and air pollution represent an opportunistic factor of the market. An increase in energy consumption and rise in greenhouse gas emissions are major factors that drive the development of green technology innovations, the report states.

Management Team

Irma Velazquez is CEO and Vice Chair at EAWD. She brings certified expertise in sustainable development and large-scale project management to the company. She formerly worked for United Nations agencies including the World Health Organization, Farmaciens Sans Frontieres, Red Cross and Crescent Societies, where she served in the positions of Information Technology Manager, Sustainable Development Manager, Programme Manager and Disaster and Crisis Management Coordinator. She has a master’s in sciences from the Erasmus University of Rotterdam. She speaks French, English and Spanish.

Ralph Hofmeier is Chief Technology Officer and Chairman at EAWD. He brings a mechanical engineering background to the company and previously served as President of Powermax Energy & Business Solutions Inc. When that company merged with EAWD, he served as President and CEO of Directors of EAWD. Over the last 20 years, he has established and developed several multinational companies in green tech distribution and commercialization. He speaks German and English.

Energy and Water Development Corp. (OTCQB: EAWD), closed Tuesday's trading session at $0.034, even for the day. The average volume for the last 3 months is and the stock's 52-week low/high is $0.021/$0.12.

Recent News

Software Effective Solutions Corp. (OTC: SFWJ)

The QualityStocks Daily Newsletter would like to spotlight Software Effective Solutions Corp. (OTC: SFWJ).

Earlier this week, the Medical Marijuana Oversight Committee in South Dakota held a meeting during which the state's director of Public Health Laboratory along with business owners discussed how illegal hemp intoxicants were affecting the state's medical cannabis industry. In particular, these parties are concerned about the proliferation of synthetically modified products derived from hemp and are being sold as delta-8 and delta-10 THC. These compounds induce a high similar to cannabis. Similar to cannabis, these synthetic products are in form of pre-rolled joints, smokable flower, edibles and vape oil. Unlike cannabis, however, the companies that produce these products aren't subject to the security, testing and labelling requirements that are imposed on the state's legal medical marijuana market. It should be noted that the legislative oversight committee didn't act on the issues raised at the meeting. Instead, members proposed that the committee recommend a legislative study for the summer. This would have to wait until summer next year because summer studies for this year are already in progress. The formulation of clear regulations for hemp derivatives such as Delta-8 THC would clear a lot of uncertainties and allow licensed companies such as Software Effective Solutions Corp. (d/b/a MedCana) (OTC: SFWJ) to determine whether these products fit into their strategic plans or not.

Software Effective Solutions Corp. (d/b/a MedCana) (OTC: SFWJ) is a global infrastructure and holding company in the cannabis industry. MedCana currently has five companies focused on pharmaceutical cannabis production, as well a software company focused on managing processes for plant-to-patient operations. The recent acquisition of an irrigation and greenhouse technology company has rounded out MedCana’s portfolio of holdings.

MedCana’s focus is on developing clients and companies in Latin America, initially in Colombia, and partnerships with laboratories, research facilities and hospitals throughout the world. MedCana is building the technology, laboratories, growing facilities and scientific teams to provide premium pharmaceutical-grade cannabis extracts to the world.

MedCana’s goal is to be the world’s premier resource for pharmaceutical cannabis products. The company believes its advantage is its global view and reach. From initial cultivation to final product, MedCana aims to help partners produce pharmaceutical CBD and other extracts that will have no equal.

The company’s mission is to utilize its technology to partner with and develop companies that provide premium pharmaceutical-grade cannabis extracts with absolute integrity, sustainability and social responsibility. MedCana’s team of pharmaceutical scientists includes some of the most respected chemists in the world. They aim to ensure that the company’s customers and partners create premium cannabis extracts that meet the growing worldwide demand. MedCana’s software is designed to ensure traceability and quality from seed to finished product.

MedCana is headquartered in Austin, Texas, with offices in Colombia.

Production

MedCana announced in May 2023 the beginning of full-scale production of non-THC cannabis for export to Europe in response to high demand in that market. This expansion comes after the successful completion of full crop cycle testing and infrastructure development at production sites in Columbia.

The recent acquisition of the assets of Tokan Corp., a software company focused on creating an enterprise resource planning (ERP) platform for the cannabis industry, and Eko2O S.A.S., a greenhouse and irrigation engineering company, has positioned MedCana for explosive growth in the region.

As a MedCana subsidiary, Eko2O SA will increase the company’s revenue potential in Central and South America. The subsidiary specializes in the construction and distribution of greenhouses and sophisticated irrigation platforms. A positive outlook has resulted from the company’s expansion as it investigates new opportunities for greenhouse and irrigation system installations in Panama and Uruguay. These opportunities are expected to accelerate Eko2O’s development and strengthen its position as a top supplier of innovative agricultural solutions in cannabis and other sectors that are quickly moving to high technology agricultural production.

In addition, MedCana has started talks with the government in Argentina about possible incentives for beginning operations in that country as part of its ongoing worldwide development strategy. Support from the Argentinean government and the start of new operations there would greatly increase MedCana’s market share in Latin America and solidify the company’s position as the market leader in the cannabis industry.

Market Opportunity

According to a report by Grand View Research, a San Francisco-based market research and consulting company, the global cannabis extract market was valued at $3.5 billion in 2022 and is expected to expand at a CAGR of 20% from 2023 to 2030 to be worth more than $15 billion.

Growing demand for cannabis extracts, including oils and tinctures, and the increased legalization of marijuana for the treatment of different chronic ailments like arthritis, Alzheimer’s, anxiety and cancer are driving the expansion of the industry. The marijuana derivative industry is flourishing due to a greater understanding of its various medical benefits.

Management Team

Jose Gabriel Diaz is CEO of MedCana. He has successfully built, grown and sold multiple telecom companies. He was senior vice president of sales at IP Communications, a national high-speed data provider. He also founded Reallinx, a national data carrier later sold to GTT Communications. Additionally, he is currently president of the A.E.M. Business and Entrepreneurship Association in Austin, Texas.

Claudio Jiménez Cartagena, QF, Ph.D. is Chief Scientific Officer at MedCana. He joined MedCana after working with Sosteli Pharma as Technical Director and serving as a director consultant for the Corporation for Agricultural Industrial Development at the University of Antioquia in Colombia. Before that, he worked as the scientific director at the Institute of Food Science & Technology. He holds a bachelor’s degree in pharmaceutical chemistry, a master’s degree in basic biomedical sciences and a doctoral degree in Environmental Engineering from the University of Antioquia.

Julián Alberto Londoño Londoño, Ph.D., is Senior Vice President of Operations at MedCana. He previously served as general manager for the Corporation for Agricultural Industrial Development, and as Chief Scientific Officer at Sosteli Pharma in the Resource Management Department. He has developed multiple U.S. patents, and recently served as senior advisor to the Secretariat of Agriculture Development for the Government of Antioquia. He holds a doctorate in Chemical Sciences from the University of Antioquia.

Software Effective Solutions Corp. (OTC: SFWJ), closed Tuesday's trading session at $0.012, even for the day. The average volume for the last 3 months is and the stock's 52-week low/high is $0.000001/$0.09.

Recent News

Horizon Fintex | Upstream

The QualityStocks Daily Newsletter would like to spotlight Horizon Fintex | Upstream

Johnny Ng Kit-Chong, a legislator in Hong Kong, is pushing the government to regulate Decentralized Autonomous Organizations (DAOs) as a way of enhancing and growing the Web3 ecosystem. This comes after a landmark court ruling where the Mantra DAO raised pertinent questions on the ownership, governance and transparency of these innovative entities. According to Monin Ung, an attorney, the accountability of Mantra DAO declined significantly in January 2021 after RioDeFi, the plaintiff, hired people to manage the DAO project in August 2020. There were accusations of misappropriation of funds. The court ruling sets a precedent showing that DAOs are not outside the scope of existing legal frameworks. This will help Hong Kong establish itself as a leader in the global Web3 space, said Ng. He believes that having clear regulations will protect investors and appeal to talented individuals and investors. Ultimately, the push for DAO regulations is about securing Hong Kong's future as a financial and technological powerhouse. Having a clear legal framework will establish the city as a global standard for how DAOs operate, encouraging other jurisdictions to follow a similar path. Jurisdictions such as the United States could also greatly benefit from establishing a clear regulatory framework for Web3, so that industry players can operate in an environment that allows them to focus on coming up with the best innovations that entities such as Horizon Fintex can quickly take up to boost their business operations.

Horizon Fintex is a software business specializing in compliant securities solutions. The company aims to facilitate the future of capital markets by leveraging the regulatory experience of Wall Street bankers and the proven track record of technology veterans to bring focus to compliance, efficiency, security and transparency.

Horizon’s flagship product is the revolutionary trading app ‘Upstream’, a MERJ Exchange Market, and the first regulated market powered by a blockchain to offer both digital securities and NFT trading. Upstream traders experience T+0 settlement, best bids and offers displayed on a transparent public orderbook that prevents predatory market practices – all from a user-friendly trading app.

Products

Horizon Fintex offers a full suite of end-to-end blockchain-enhanced software solutions to create a seamless experience for both issuers and investors. Its product suite includes:

  • Securitization & IssuanceETSware is an end-to-end Electronic Trading System streamlining capital raising from primary issuance through compliant secondary trading.
  • KYC Compliance OnboardingKYCware is a white label Know Your Customer (KYC) and Anti-Money Laundering (AML) compliance software solution offering best-in-class cryptographic security to compliantly onboard and verify user identity through a smartphone application.
  • AML Screening SoftwareAMLCop offers advanced Anti-Money Laundering (AML) software to streamline the verification of user details against a proprietary database of global sanctions, politically exposed persons (PEPs) and watchlists.
  • Cap. Table Management ToolsCustodyWare equips registered U.S. transfer agents with next-generation cap. table management software to manage securities on behalf of their clients pursuant to an SEC-registered or exempt securities offering.
  • Exchange & Trading App TechnologyOpen Order Book offers Ethereum blockchain securities exchange software to power the next generation of trading venues for digital assets.

Upstream – The Horizon-Powered Trading App

Upstream is a joint venture with MERJ Exchange (merj.exchange), an affiliate of the World Federation of Exchanges.

Upstream aims to be the premiere global trading hub offering issuers around the world exposure to a digital-first investor base that can trade using USDC digital currency along with credit, debit, PayPal, and USD (fiat) to increase liquidity and enhance price discovery; while also offering investors access to dual-listed companies, IPOs, crowdfunded companies, U.S. & Int’l. equities, digital coupons and NFTs directly from a user-friendly trading app.

Upstream aims to unlock liquidity for investors of all levels while offering industry-leading levels of transparency, accessibility and investor protections enforced using Ethereum blockchain technology.

Management Team

Brian Collins is the CEO of Horizon Fintex. He founded the company in 2010. From 1999-2010, Mr. Collins was CEO of Abbey Technology in Switzerland, specializing in the design of trading software for Swiss banks. Prior to this, he worked for Credit Suisse in Zürich, designing and building proprietary equity trading solutions. Mr. Collins graduated in 1990 with a BS in Computer Systems from the University of Limerick, Ireland.

Mark Elenowitz is the company’s President. He is a Wall Street veteran with over 29 years of experience. Mr. Elenowitz was the co-founder of a U.S. broker dealer and is Managing Director of two U.S. broker dealers, responsible for advising clients on compliance, capital structure and capital market navigation. He was responsible for leading the first successful Reg A+ IPO of a company to list on the NYSE and others which listed directly onto Nasdaq. He is a noted speaker at Small Cap and Reg A events, including the SEC Small Business Forum, and has been profiled in BusinessWeek and CNBC, as well as several other publications. Mr. Elenowitz is a graduate of the University of Maryland School of Business and Management with a BS in Finance and holds Series 24, 62, 63, 79, 82 and 99 licenses.

Dr. Andrew Le Gear is the CTO of Horizon Fintex. Prior to joining the company in 2013, he worked as a software engineer with Dell Inc. (2012-2013) and Lehman Brothers and Nomura Plc. (2007-2012). Dr. Le Gear was a co-founder of Juneberi Ltd., a research-driven software tech start-up (2004-2007). He graduated in 2006 with a Ph.D. in Computer Science from the University of Limerick, Ireland.

Peter Hall is the company’s CIO. Prior to joining Horizon Fintex in 2011, he worked at Microsoft (2008-2011), Atos Origin (2004-2008) and AIT Group Plc. (1998-2002). Mr. Hall has held CISSP certification since 2010. He graduated from the University of Sheffield, UK in 1995 and earned an MS from the University College London in 2006.

Mike Boswell is the CFO of Horizon Fintex. A Wall Street veteran, he co-founded a U.S. broker dealer and served as Chief Compliance Officer. Mr. Boswell was also Managing Director of TriPoint Capital Advisors, a merchant banking and financial consulting company, and CFO of Mission Solutions Group, a privately held defense sector firm. He earned an MBA from John Hopkins University and a BS in Mechanical Engineering from the University of Maryland. Mr. Boswell holds Series 24, 62, 63, 79, 82 and 99 licenses.

Recent News

chart

McEwen Mining Inc. (NYSE: MUX) (TSX: MUX)

The QualityStocks Daily Newsletter would like to spotlight McEwen Mining Inc. (NYSE: MUX) (TSX: MUX).

McEwen Mining (NYSE: MUX) (TSX: MUX), a gold and silver producer with operations in Nevada, Canada, Mexico and Argentina, has reached an agreement with YPF Energía Eléctrica S.A. (YPF Luz). The agreement is for YPF Luz to power McEwen Copper Inc.'s large Los Azules copper project with renewable energy. According to the announcement, the agreement covers the supply of renewable energy through a high-voltage transmission line; YPF Luz will be responsible for the development and financing of the line. An Argentine company, YPF Luz is a leader in power generation that has been in operation since 2013.

"Los Azules will play a critical role for Argentina and the world by significantly contributing to decarbonization," said McEwen Copper vice president Michael Meding in the press release. "The geological potential of the project will position San Juan on the international map of resources for the energy transition, and in this context, YPF Luz is a strategic ally to help us achieve our goal of being 100% renewable."

To view the full press release, visit https://ibn.fm/HVZ1G

McEwen Mining Inc. (NYSE: MUX) (TSX: MUX) is an asset rich diversified gold and silver producer in the Americas with a large exposure to copper through its subsidiary, McEwen Copper, owner of the Los Azules copper deposit in Argentina, believed to be the 8th largest undeveloped copper resource in the world.

Led by a management team with a track record of success, MUX owns and operates mines in some of the most prolific gold producing regions of the Americas. The company proactively took cost-saving measures months ago to lower expenses and increase production across its portfolio of gold assets, driving some production costs below industry averages. Gold and copper prices, already in an upswing, are forecast to enter an explosive uptrend over the next couple years. Drawing from its experience, McEwen Mining planned, prepared and laid the groundwork to capitalize on this emerging opportunity.

The company currently holds a Zacks Rank #1 (Strong Buy), placing it in the top 5% of over 4,000 stocks ranked by Zacks, based on trends in earnings estimate revisions and EPS surprises. Seldom is management so aligned with investors’ interests and committed to the company’s success. With a combined investment of over $220 million, CEO Rob McEwen holds a 17% ownership stake in McEwen Mining and a 13% ownership in McEwen Copper. Acclaimed in the mining industry, McEwen founded Goldcorp, where he increased the company’s market capitalization 160 times – from $50 million to over $8 billion. That same vision and tenacity led MUX in creating McEwen Copper.

For McEwen Mining shareholders, beyond the company’s exposure to gold upsurges, its 47.7% stake in McEwen Copper is expected to be a blockbuster, turbocharging MUX by creating the world’s next prolific copper unicorn.

McEwen Copper

With continuous industrial need, new critical demand for copper is rapidly emerging, increasingly driven by the green energy transition. The price of copper rose from a low of about $2 per pound in 2020 to over $4.60 per pound in May 2024, and strong demand is expected to intensify. A study by S&P Global, titled The Future of Copper: Will the Looming Supply Gap Short-circuit the Energy Transition?, projects global copper demand to nearly double over the next decade, from 25 million metric tons today to about 50 million metric tons by 2035. Based on current trends, S&P Global forecasts annual supply shortfalls to reach nearly 10 million metric tons in 2035.

McEwen Mining owns a 47.7% equity stake in McEwen Copper, the holder of a 100% interest in the Los Azules copper project in San Juan, Argentina, which is ranked the 8th largest undeveloped copper deposit in the world. Current copper resources at Los Azules are estimated at 10.9 billion pounds at a grade of 0.40% Cu (Indicated category) and an additional 26.7 billion pounds at a grade of 0.31% Cu (Inferred category). McEwen Copper also owns a copper exploration project in Nevada, USA, called Elder Creek.

In a 2023 Preliminary Economic Assessment (PEA), Los Azules was estimated to have a 27-year life, producing an average of 322 million lbs. of copper cathode annually, at a cash cost of $1.07 per lb. of copper, in the lowest quartile of the copper cost curve. The project could ultimately become an even larger mine with a longer life, since the extent of mineralization has not been fully assessed on the property.

The project’s 2023 PEA presents a distinctly different development strategy from a prior PEA published in 2017. By proposing a heap leach project using solvent extraction-electrowinning instead of the previously detailed mine with a conventional mill and flotation concentrator, McEwen Copper aims to decrease its environmental footprint and reduce permitting risk, albeit with a lower overall copper recovery, slightly higher unit costs and a delay in immediate cashflow due to extended leach cycles.

After securing a $25 million investment from mining giant Rio Tinto’s technology arm, Nuton LLC, McEwen Copper closed its non-brokered, private placement offering of $82 million in August 2022. Shortly after, in February 2023, Nuton agreed to invest an additional $30 million into McEwen Copper, and in October 2023, Nuton once again expanded its stake, investing an additional $10 million to bring its ownership position in McEwen Copper to 14.5%.

“We are extremely pleased to have Nuton’s strong continued participation in McEwen Copper,” Rob McEwen stated in a news release. “Together we are exploring new technologies that save energy, water, time and capital in the pursuit of delivering green copper to Argentina and the world, a product that will contribute to the electrification of transportation and the protection of our atmosphere.”

Also in February 2023, FCA Argentina S.A., a subsidiary of Stellantis N.V., one of the world’s leading automakers, invested ARS $30 billion in McEwen Copper. In October 2023, Stellantis invested an additional ARS $42 billion, bringing its current stake in McEwen Copper to 19.4%.

“We are delighted to have Stellantis as a partner in the future development of our Los Azules copper project,” Rob McEwen said of the investment. “Together, we share a vision to build a mine for the future based on regenerative principles that can achieve net-zero carbon emissions by 2038.”

Following the capital raise, McEwen Copper is well-funded to advance its Los Azules Project, with a Feasibility Study planned for Q1 2025. MUX strategically reduced its interest to increase its treasury, in order to reduce debt and fund the further development of its gold and silver assets.

Gold & Silver Projects

The Fox Complex

McEwen Mining owns a 100% stake in the Fox Complex in the heart of a prolific gold district in Timmins, Canada.

“When MUX bought the Fox Complex, in late 2017, it was a distressed asset with a history of high operating cost/oz. While it has taken longer than I expected, the cost to produce an ounce of gold is significantly lower,” CEO Rob McEwen stated in a news release.

McEwen Mining issued 2024 guidance for its cash cost/oz at the Fox Complex of $1,225-1,325 on annual production of 40,000-42,000 GEOs. Fox Complex produced 44,450 GEOs in 2023, which was within the company’s guidance range.

Located in one of the most prolific gold production areas in the world, along the Destor-Porcupine Fault Zone within the Abitibi Greenstone Belt, the Fox Complex includes the Black Fox mine and Froome mine which together have yielded over 1,000,000 ounces of gold to date. Also, the complex includes the Grey Fox and Stock deposits that have over 1,800,000 ounces in gold resources. The 2.7-billion-year-old Abitibi Greenstone Belt, formed by ancient volcanic activity, has proved to be one of the world’s richest and most abundant gold regions, with a total gold content currently estimated at over 300 million ounces.

In 2024, MUX commenced development of underground ramp access to the Stock orebodies at the Fox Complex. This development will become the primary source of feed following the completion of mining the Froome deposit in 2026. As part of the future mining sequence initiative, the company has already reported a 31% year-over-year increase of gold resources at Stock West and Stock Main (historical Stock Mine), with confirmation of good grading structures plunging to depth. It has also identified Stock East as a potential new near-term source of future revenue.

The Gold Bar Mine

McEwen Mining owns a 100% stake in the Gold Bar mine, located in an area well known for gold production, the southern Roberts Mountains of the Battle Mountain-Eureka-Cortez gold trend in Eureka County, Central Nevada. The Gold Bar mine is on the same geological structure, 25 miles south of Nevada Gold Mines, a Barrick-Newmont joint venture, part of the Cortez-Goldrush complex. This complex contains estimated reserves and resources of over 50 million gold ounces, with an annual production of 1,000,000 gold ounces.

Gold Bar had been mined between 1991 and 1994, producing 134,000 gold ounces. A new facility was built by MUX in 2019. Gold Bar accounted for 42,700 GEOs in 2023, within the company’s guidance for the year. For 2024, McEwen Mining issued guidance of 40,000-43,000 at a cash cost of $1,450-1,550. The first half of the year is expected to deliver higher production relative to the second half, due to a scheduled waste stripping phase in the Pick pit, in preparation for the 2025 mining program.

Notably, in April 2024, McEwen Mining announced its entry into a definitive agreement and plan of merger with Timberline Resources Corporation (TSX.V: TBR) (OTCQB: TLRS) in a transaction valued at roughly $18.8 million. The merger with Timberline is expected to augment McEwen’s existing portfolio of development and exploration projects in Nevada, leveraging synergies between Timberline’s projects and the Company’s Gold Bar mine.

El Gallo/Fenix

Project Fenix is the proposed redevelopment plan for McEwen Mining’s El Gallo Complex in Mexico. There is a long history of mining in this region. MUX began operating it as an open pit, heap leach mine in 2013, which produced 281,000 gold equivalent ounces at average cash cost of $655 per ounce. Due to the transition to deeper sulfide mineralization that is not amenable to heap leaching, mining activities ceased in the second quarter of 2018 and residual heap leaching followed until mid-2022. The redevelopment plan envisions constructing a mill at the existing mine site that will initially reprocess the existing heap leach material, then transition to open pit mining and processing of the sulphide mineralization. The company recently acquired a complete process plant on very advantageous terms that has considerably reduced the projected capital requirements for the project.

CEO Rob McEwen stated in a news release, “This acquisition has made Fenix more attractive to build and could provide a new long life mine for McEwen Mining.”

The initial development approach is to build a mill to reprocess the material on the heap leach pad and produce approximately 17,000 oz of gold annually for eight years. Construction of the Fenix project is expected to begin in the second half of 2024.

San José Mine

McEwen Mining is a 49% owner and non-operator of the San José gold and silver mine, located in Santa Cruz province, Argentina, encircling Newmont’s prolific Cerro Negro (approx. 300,000 gold ounces produced in 2023). This high-grade underground mine has been operating since 2007 and currently has an expected life of six years with a reserve grade of 296 gpt silver and 5.4 gpt gold.

Exploration is continuing to extend high-grade veins and discover new veins at the complex. San José’s drilling programs to define additional resources and reserves have a long history of success due to a high vein density, aided by good geophysical response from hidden veins.

Production guidance for 2024 for MUX’s 49% interest is 50,000-60,000 GEOs. As a minority shareholder in the mine, MUX equity accounts for its investment in San José, and receives 49% of the dividends from the mine’s free cash flow.

Market Outlook

Mining stocks suffered significant losses in the wake of the COVID-19 pandemic. However, this has turned, and many analysts now forecast a gold bull market in 2024 and beyond.

“The operating challenges we faced in recent years have severely damaged our credibility with our shareholders and the market. As a result, few investors have taken a close look recently at our assets,” Rob McEwen said in a news release. “If they did, I believe some would see the potential value that I see today… I believe there is considerable potential value in MUX, and that is a big reason why I have a personal financial commitment of $220 million in MUX and McEwen Copper.”

Management Team

Robert R. McEwen is Chairman, CEO and Chief Owner of McEwen Mining. He has been associated with the gold industry all his career, with his first 18 years in the investment industry and, since 1990, as CEO of several gold mining companies. He founded Goldcorp and took that company from a $50 million market capitalization to more than $8 billion. He owns 17% of McEwen Mining and is in complete alignment with investors – his investment in MUX and McEwen Copper is $220 million and he takes an annual salary of only $1. He was awarded the Order of Canada and the Queen Elizabeth’s Diamond Jubilee Award, was inducted into the Mining Hall of Fame, was named an Ernst and Young Entrepreneur of the Year and has Honorary Doctor of Law degrees from York University and Western University.

William Shaver is interim COO and a Director of McEwen Mining. He has decades of management and executive experience in mine design, construction and operations. He was a founder of Dynatec Corporation, which became one of the leading contracting and mine operating groups in North America. In 2013, he was recognized as Ernst and Young Entrepreneur of the Year. Most recently, he served as COO of INV Metals. He is a Professional Engineer with a B.Sc. in Mining Engineering from Queens University.

Perry Ing is interim CFO at McEwen Mining. He has 25 years of experience in the Canadian mining industry. Over the past 15 years, he has held positions as CFO of Mountain Province Diamonds, Kirkland Lake Gold and McEwen Mining. Prior to that, he worked at Barrick Gold and Goldcorp and started his career in the mining practice at PwC. He has a Bachelor of Commerce from the University of Toronto and is a Chartered Professional Accountant in Canada and Certified Professional Accountant in the U.S.

Adrian Blanco S. is the company’s Director of Operations for America and Mexico. He has extensive international experience in several industrial sectors and has held executive positions in Mexico, the United States, Peru and Argentina. He joined the McEwen Mining team in 2015 and has led a successful business transformation toward operational discipline, best business practices and financial profitability at subsidiaries Compañia Minera Pangea and McEwen Mining Nevada. He graduated from an Executive Management Program at IPADE and Harvard Business School.

Michael Meding is Vice President and General Manager of McEwen Copper. He has over 20 years of international experience, primarily with major mining companies such as Barrick Gold and Trafigura, including extensive experience with project development and operations in Argentina. While at Barrick Gold’s Veladero mine in Argentina, Mr. Meding played a key role in the turnaround, extension of the mine life and subsequent strategic partnering with Shandong Gold. He holds an MBA from Indiana University in Pennsylvania and an MBA from the Leipzig Graduate School of Management in Germany.

McEwen Mining Inc. (NYSE: MUX), closed Tuesday's trading session at $9.33, off by 1.686%, on 428,320 volume. The average volume for the last 3 months is 580,944 and the stock's 52-week low/high is $5.92/$12.50.

Recent News

Lexaria Bioscience Corp. (NASDAQ: LEXX)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (NASDAQ: LEXX).

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, is announcing receipt of the first results from human pilot study #2, GLP-1-H24-2. According to the announcement, the company's DehydraTECH(R)-processed Rybelsus(R) evidenced a trend toward higher overall absorption under fed conditions compared to Rybelsus(R) that was not processed with DehydraTECH. The DehydraTECH-processed Rybelsus(R) evidenced higher semaglutide levels in 17 of the 19 blood draws taken until the 24-hour completion of the study, averaging 18.8% higher semaglutide levels over the course of the study compared to Rybelsus(R) alone. However, the announcement noted that the differences were variable and not significant statistically with such a small sample size.

"Lexaria is delighted that our contracted clinical research organization was able to complete the active phase of the study on schedule," commented Chris Bunka, CEO of the company. "The results of these study arms have shown that DehydraTECH appears to continue to offer pharmacokinetic improvements even when dosed under fed conditions, reinforcing DehydraTECH's beneficial delivery kinetics."

To view the full press release, visit https://ibn.fm/ZTyaS

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator in drug delivery platforms. The company’s patented technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules. DehydraTECH promotes fast-acting, less expensive and more effective oral drug delivery and has been thoroughly evaluated through in vivo, in vitro and human clinical testing.

DehydraTECH is covered by 21 issued and more than 50 pending patents in over 40 countries around the world. Lexaria’s first patent was issued by the U.S. Patent and Trademark Office in October 2016 (US 9,474,725 B1), providing 20 years of patent protection expiring June 2034. Multiple patents have been awarded since then and are expected in the future.

Lexaria has also collaborated with the National Research Council (NRC), the Canadian government’s premier research and technology organization. The company has been granted patent protection for specific delivery of nicotine, vitamins, NSAIDs, antiviral drugs, cannabinoids and more.

Lexaria began developing DehydraTECH in 2014 and has since continued to strengthen and broaden the technology. The company has no plans to create or sell Lexaria-branded products containing controlled substances. Instead, Lexaria licenses its technology to other companies around the world to offer consumers the best possible performance across an array of ingestible product formats.

The company’s technology is best thought of as an additional layer that providers of consumer supplements, prescription and non-prescription drugs, nicotine and CBD products can utilize to improve the effectiveness of their own existing or planned new offerings. Lexaria has licensed DehydraTECH to multiple companies, including a world-leading tobacco producer for the research and development of smokeless, oral-based nicotine products, and for use in industries that produce cannabinoid beverages, edibles and oral products.

DehydraTECH is suitable for use with a wide range of product formats including pharmaceuticals, nutraceuticals, consumer packaged goods and over-the-counter capsules, pills, tablets and oral suspensions.

DehydraTECH Technology

Lexaria’s DehydraTECH is designed specifically for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients. DehydraTECH increases their effectiveness and improves the way active pharmaceutical ingredients enter the bloodstream. The major benefits to a subject ingesting a DehydraTECH-enabled drug or consumer product can be summarized by the following:

  • Speeds up delivery – the effects of the product are felt by the subject in just minutes.
  • Increases bioavailability – the technology is much more effective at delivering a drug or product into the bloodstream.
  • Increases brain absorption – animal testing suggests significant improvement in the quantity of drug delivered across the blood-brain barrier.
  • Improves drug potency – more of the ingested product is made available to the body, so lower doses are required to achieve the desired effect.
  • Reduces drug administration cost – lower doses mean lower overall drug costs.
  • Masks unwanted taste – the technology eliminates or reduces the need for sweeteners.

Lexaria has demonstrated in animal studies a propensity for DehydraTECH technology to elevate the quantity of drug delivered across the blood-brain barrier by as much as 1,900 percent, initiating additional new patent applications and opening possibilities for improved drug delivery.

Since 2016, DehydraTECH has repeatedly demonstrated, with cannabinoids and nicotine, the ability to increase bio-absorption by up to five to 10 times, reduce time of onset from one to two hours to just minutes, and mask unwanted tastes. The technology is to be further evaluated for additional orally administered bioactive molecules, including antivirals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and nicotine.

Market Outlook

Lexaria’s ongoing research and development efforts are mainly focused on development of product candidates across several key segments:

  • Oral Cannabinoids – a market estimated to be worth $18.4 billion in 2021 and expected to reach $46.2 billion by 2025.
  • Antivirals – an estimated $52.1 billion market in 2021 that’s expected to grow to $66.7 billion by 2025.
  • Oral Mucosal Nicotine – smokeless tobacco products, a $13.6 billion market in 2018, is forecast to grow at 7.2 percent annually through 2025.
  • Human Hormones – estrogen and testosterone replacement therapies represented a $21.9 billion market in 2019, with a forecast CAGR of 7.7 percent through 2027.
  • Ibuprofen and Naproxen – NSAID sales totaled $15.6 billion globally in 2019 and are projected to reach $24.4 billion by 2027.
  • Vitamin D3 – the global market size was $1.1 billion in 2021, growing at 7 percent per year and expected to reach $1.7 billion in 2026.

Management Team

Chris Bunka is Chairman and CEO of Lexaria Bioscience Corp. He is a serial entrepreneur who has been involved in several private and public companies since the late 1980s. He has extensive experience in the capital markets, corporate governance, mergers and acquisitions, as well as corporate finance. He is named as an inventor on multiple patent innovations.

John Docherty, M.Sc., is the President of Lexaria. He is a pharmacologist and toxicologist, and a specialist in the development of drug delivery technologies. He is the former president and COO of Helix BioPharma Corp. (TSX: HBP). He is named as an inventor on multiple issued and pending patents.

Greg Downey is Lexaria’s CFO. He has more than 35 years of diverse financial experience in the mining, oil and gas, manufacturing, and construction industries, and in the public sector. He served for eight years as CFO for several public companies and has provided business advisory and financial accounting services to many large organizations.

Gregg Smith is a strategic advisor to Lexaria. He is a founder and private investor with Evolution VC Partners. He is a member of the Sand Hill Angels and held previous investment banking roles with Cowen and Company and Bank of America Merrill Lynch.

Dr. Philip Ainslie serves as a scientific and medical advisor to Lexaria. He is co-director for the Centre for Heart, Lung and Vascular Health, Canada. He is also Research Chair in Cerebrovascular Physiology and Professor at the School of Health and Exercise Sciences, Faculty of Health and Social Development at the University of British Columbia.

Lexaria Bioscience Corp. (LEXX), closed Tuesday's trading session at $2.87, off by 1.0345%, on 59,449 volume. The average volume for the last 3 months is 201,746 and the stock's 52-week low/high is $0.844/$6.85.

Recent News

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system. The company today announced that CEO John Climaco will present and discuss recent corporate events at the upcoming LIVE! with Webull Corporate Connect: Virtual Biotech Investor Webinar. The presentation is scheduled for Wednesday, August 28, 2024, at 3:20 p.m. ET.

To register for the live webinar, visit https://ibn.fm/JXz89

To view the full press release, visit https://ibn.fm/GfqLq

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (http://nnw.fm/eDUjp).

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Tuesday's trading session at $0.1672, off by 7.1111%, on 2,114,080 volume. The average volume for the last 3 months is 5.418M and the stock's 52-week low/high is $0.0955/$6875.00.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.